Pregnant women in Opioid maintenance treatment (OMT): Maternal and neonatal outcomes by Lund, Ingunn Olea
 
 
PREGNANT WOMEN IN OPIOID MAINTENANCE 
TREATMENT (OMT): MATERNAL AND NEONATAL 
OUTCOMES 
 
 
Ingunn Olea Lund 
SERAF 
Norwegian Centre for Addiction Research 
Institute of Clinical Medicine 
Faculty of medicine 
University of Oslo 
Oslo, Norway 
2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Ingunn Olea Lund, 2013 
 
 
Series of dissertations submitted to the  
Faculty of Medicine, University of Oslo 
No. 1515 
 
ISBN 978-82-8264-503-4 
 
 
All rights reserved. No part of this publication may be  
reproduced or transmitted, in any form or by any means, without permission.   
 
 
 
 
 
 
 
 
Cover: Inger Sandved Anfinsen. 
Printed in Norway: AIT Oslo AS.  
 
Produced in co-operation with Akademika publishing.  
The thesis is produced by Akademika publishing merely in connection with the  
thesis defence. Kindly direct all inquiries regarding the thesis to the copyright  
holder or the unit which grants the doctorate.   
 
 ACKNOWLEDGEMENTS ..................................................................................................................................... I 
ABSTRACT ....................................................................................................................................................... III 
NORWEGIAN SUMMARY ................................................................................................................................. VI 
LIST OF PAPERS ............................................................................................................................................... IX 
ABBREVIATIONS ............................................................................................................................................... X 
1.0 INTRODUCTION .......................................................................................................................... 1 
1.1 Opioid dependence and OMT ..................................................................................................................... 1 
1.2 Opioid dependence and pregnancy ............................................................................................................ 1 
1.3 The role of the partners of pregnant OMT women ..................................................................................... 4 
1.4 Prescription drug use among pregnant OMT women ................................................................................. 4 
1.5 Maternal and neonatal outcomes from exposure to different OMT drugs ................................................. 5 
1.6 Knowledge gaps ......................................................................................................................................... 6 
2.0 OBJECTIVES .................................................................................................................................. 7 
3.0 MATERIAL AND METHODS ..................................................................................................... 8 
3.1 Design ........................................................................................................................................................ 8 
3.2 Sources of data ........................................................................................................................................... 8 
3.2.1 The national OMT cohort......................................................................................................................... 8 
3.2.2 The Medical Birth Registry of Norway (MBRN) ........................................................................................ 9 
3.2.3 The Norwegian Prescription Database (NorPD) ..................................................................................... 10 
3.2.4 Papers included in the small clinical review ........................................................................................... 11 
3.3 Study population ...................................................................................................................................... 11 
3.4 Study instruments .................................................................................................................................... 14 
3.5  Data analysis ........................................................................................................................................... 19 
3.6 Ethics ........................................................................................................................................................ 20 
4.0 RESULTS ..................................................................................................................................... 22 
4.1 Aim I: Substance abuse and related problems .......................................................................................... 22 
4.2 Aim II: Psychiatric problems ..................................................................................................................... 23 
4.3 Aim III: Prescription drug use.................................................................................................................... 25 
 4.4 Aim IV: Maternal and neonatal outcomes from exposure to different OMT drugs ................................... 28 
4.5 Brief summary of main findings ................................................................................................................ 28 
5.0 DISCUSSION ............................................................................................................................... 30 
5.1 Methodological considerations ................................................................................................................ 30 
5.1.1 Type 2 error ........................................................................................................................................... 30 
5.1.2 Selection bias ........................................................................................................................................ 30 
5.1.3 Information bias .................................................................................................................................... 32 
5.1.4 Confounding .......................................................................................................................................... 33 
5.1.5 Instruments used ................................................................................................................................... 34 
5.1.6 Classifications and labeling .................................................................................................................... 36 
5.1.7 External validity ..................................................................................................................................... 36 
5.1.8 Strengths ............................................................................................................................................... 37 
5.2 Discussion of results ................................................................................................................................. 38 
5.2.1 Aim I: Substance abuse .......................................................................................................................... 38 
5.2.2 Aim II: Psychiatric problems .................................................................................................................. 40 
5.2.3  Aim III: Prescription drug use ................................................................................................................ 42 
5.2.4. Aim IV: Maternal and neonatal outcomes from exposure to  different OMT drugs .............................. 44 
6.0 FUTURE RESEARCH ................................................................................................................ 46 
7.0 CONCLUSIONS .......................................................................................................................... 48 
REFERENCES .................................................................................................................................... 49 
ERRATA ............................................................................................................................................. 59 
PAPERS I-IV ...................................................................................................................................... 60 
 
 
I 
 
ACKNOWLEDGEMENTS 
This thesis is based on work undertaken between 2009 and 2012, at the Norwegian Centre for 
Addiction Research (SERAF) University of Oslo. The study was funded by The Norwegian Research 
Council (Project number 190425). 
 
This project was made possible with the help from many collaborators. First I would like to thank my 
main supervisor, Professor Edle Ravndal. She has provided everything a PhD student could ask for 
from a supervisor.  She is strong, fun, and outspoken and I always felt motivated when leaving her 
office after a discussion.  I would also like to thank my second supervisor, Professor Svetlana 
Skurtveit. She has been supportive, patient and fun to work with. She has taught me everything I 
know about epidemiological research and has been a great inspiration to me! 
 
I am very grateful to all my co-authors for their contributions. Thank you Monica Sarfi and Gabrielle 
Welle-Strand for welcoming me as part of the team and for sharing your knowledge on OMT and 
pregnancy with me. I would also like to thank to Marte Handal for your support, positivity and 
patience!  
 
Being a PhD student at SERAF has been fun. I am grateful for the extremely competent and 
supportive environment. It has been an inspiration to work with such great colleagues. A special 
thanks goes to the research director at Seraf, Professor Jørgen Bramness for being an encouraging 
and ambitious leader. This in combination with his scientific expertise, enthusiasm, energy and 
humor makes him a great research director. A huge thank you to my office roommate, Anne Bukten: 
You are the best! Thank you for your continuous support, cheering and for having hundreds of 
coffees with me! You have made my days as a PhD student a lot more enjoyable.  Thank you, Sigrid 
and Håvar for your support and advise. I would also like to acknowledge the administrative staff at 
II 
 
SERAF; Pål, Pernille, Hela , Arild, Randi, Shakoor and Julie for your help with small and large 
problems. Additional thanks to Hela, for running&sushi Tuesdays.  
 
I would like to express my thanks to the Fulbright Foundation and the American Women’s Club for 
awarding me the scholarships for my 1 year research stay in the U.S. at Johns Hopkins Medicine and 
RTI International. Thanks to Margret Andersen for help during the scholarship application process. 
 
I would like to thank Michelle Tuten, Heather Fitzsimons and Meg Chisolm at the Center for 
Addiction and Pregnancy, Johns Hopkins Medicine for making my stay there a productive one. I 
would also like to thank Karol Kaltenbach at Thomas Jefferson University for helping me make the 
most out my visit at the Family Center in Philadelphia. A very special thank you to my mentor in the 
U.S., Professor Hendree Jones. It has been a great experience working with her this past year. She is 
a brilliant researcher with a great sense of humor, an impressive energy level and positivity. She is a 
great inspiration and role model that generously welcomed me into her family during my stay in the 
U.S. Thanks to Wendee Wechsberg at RTI International and her staff for making me feel like part of 
the team during my stay there. Thanks to Andrea Gordon at the University of South Australia for 
proof reading, advice and support. 
 
I would like to thank my family and friends for always believing in me, supporting me and being 
patient with me during my PhD ups and downs. Last, but certainly not least I want to thank my 
partner, Njål. Thank you for always making me laugh and dragging me out single track mountain 
biking and skiing. Thank you for being surprisingly keen to discuss my work and offer valuable 
feedback, for proof reading and commenting on my papers. Thank you also for making fantastic 
dinners!  Without your support, completing my PhD would have been so much harder.  
III 
 
ABSTRACT 
Background 
The Norwegian Health Care system significantly differs from international settings such as the U.S., 
where the majority of research on pregnant opioid dependent women is conducted. Hence results 
from international research may not be generalized to the Norwegian setting. Therefore, to be able 
to offer the best possible care, it is of great importance to investigate how pregnant women in opioid 
maintenance treatment (OMT) in Norway are faring in regards to continued substance use and 
psychiatric problems both during pregnancy and sometime after the children are born. Secondly, the 
partners of pregnant opioid dependent women may contribute to the woman’s drug use relapses as 
well as to improved treatment outcomes and how the woman will cope as a mother.  However, they 
are rarely included in studies on pregnant opioid dependent women. Moreover, there is a lack of 
studies offering a compete overview of use of prescription drug use prior to, and during pregnancy 
among OMT women. Lastly, maternal and neonatal outcomes after exposure to buprenorphine + 
naloxone has not been compared to other medicinal treatments for opioid dependence such as 
buprenorphine, methadone and methadone assisted withdrawal. Despite the lack of research on 
this, buprenorphine + naloxone is prescribed to pregnant opioid dependent women several places in 
the U.S. 
Study aims 
The aims of the present thesis were to investigate substance abuse and psychiatric problems in a 
national cohort of pregnant OMT women and their partners. Moreover, to investigate use of 
prescription drugs among women in OMT prior to, and during pregnancy. Furthermore, to 
investigate maternal and neonatal outcomes from use of buprenorphine + naloxone versus 
methadone, buprenorphine and methadone-assisted withdrawal.  
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Materials and methods 
Different study designs were utilized for this thesis. Paper I and II were based on a cohort design; 38 
pregnant OMT women and their partners (n= 23) were included. Paper III was based on a national 
cohort design, using the Norwegian birth registry and the Norwegian prescription database: 138 
women and 159 pregnancies were included. Paper IV, a clinical mini-review, was based on published 
articles including both randomized controlled trials (RCTs) and retrospective studies.  
Results 
Use of illegal drugs among the women and their partners were low both during third trimester of 
pregnancy and one year after birth. One woman reported using illegal substances at each time 
interval. Two partners reported using illegal substances prior to the interview during third trimester. 
One year after one partner reported such use. Among the women, problem drinking increased from 
0-15 % from third trimester to one year after birth. In contrast, problem drinking was significantly 
reduced (p <.01) among the partners, from 30-16 % from the third trimester to one year after birth. 
A majority of the women (81 %) and the partners (57 %) had experienced emotional and/or physical 
and/or sexual abuse earlier in life. Furthermore, most women (92 %) and their partners (91 %) had 
experienced psychological problems earlier in life. There was a significant reduction (p <.01) of 
depressive symptoms in the women from pregnancy to six months after the children were born and 
a tendency towards an increase at two years after birth. Among the partners, there was significant 
reduction (p < .05) in psychiatric problems from third trimester to one year after the children were 
born. Most pregnant OMT women (81 %) were dispensed prescription drugs during pregnancy. The 
most common prescription drugs were antiinfectives (48 %) and drugs acting on the central nervous 
system (45 %). Benzodiazepines were used by 26.4 % of women during pregnancy, whereas only 5 % 
of women used antidepressants during pregnancy. Malformations were significantly more common 
(p< .05) among neonates whose mother received co-medication with drugs with abuse potential 
during pregnancy. There were no significant differences in maternal outcomes in women that used 
buprenorphine + naloxone compared to buprenorphine, methadone and methadone-assisted 
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withdrawal. Birth length was significantly shorter (p < .001) in the buprenorphine + naloxone group 
compared to neonates in the buprenorphine group.  
Conclusion 
Most pregnant OMT women in Norway and their partners were able to abstain from using illegal 
drugs both during pregnancy and after the children are born. Psychiatric problems among the OMT 
women and their partners appears to be reduced from pregnancy to after the children were born. 
This may influence both treatment outcome and parenting abilities in a positive way. Pregnant OMT 
women used more prescription drugs than pregnant women in the general population. Co-
medication with drugs with abuse potential may increase the risk of malformations in neonates and 
should be addressed further. Although there were no significant difference in maternal outcomes 
and few on neonatal outcomes when comparing buprenorphine + naloxone to buprenorphine, 
methadone and methadone assisted withdrawal, the results should be considered preliminary due to 
a very small sample in the buprenorphine + naloxone group.  
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NORWEGIAN SUMMARY 
Bakgrunn 
Helsevesenet og behandlingstilbudene i Norge er svært forskjellig fra for eksempel USA, hvor mye av 
forskningen på gravide kvinner i LAR er gjort; resultatene fra internasjonale studier kan muligens ikke 
overføres til norske forhold.  For å kunne tilby best mulig behandling til gravide i LAR i Norge og deres 
familier er det viktig å undersøke bruk av rusmidler og psykisk helse både under svangerskap og etter 
at barnet er født. Partnere kan i stor grad påvirke behandlingsutfall hos opiatavhengige kvinner; de 
kan bidra til både tilbakefall og økt sjanse for et godt utfall og påvirke hvordan en kvinne klarer seg 
som mor. Likevel er de sjelden inkludert i studier om gravide opiatavhengige kvinner.  Også 
forskrevne legemidler kan misbrukes, og noen kan være skadelige for fosteret. På den andre siden er 
det mulig at noen gravide kvinner i LAR ikke mottar de legemidlene de trenger fordi noen leger er for 
forsiktige og mangler kunnskap om LAR og ko-medisinering. Svangerskapsutfall og utfall hos nyfødte 
etter eksponering til buprenorfin + naloxone gjennom svangerskapet har ikke tidligere blitt 
sammenlignet med utfall etter eksponering til andre medikamentelle behandlinger for 
opiatavhengighet: buprenorfin, metadon eller metadonassistert nedtrapping. Likevel benyttes dette 
medikamentet til behandling av opiatavhengighet hos gravide kvinner flere steder i USA.  
Forskningsspørsmål 
Målene i denne studien var å undersøke rusmisbruk og psykiske plager i en nasjonal kohort gravide 
LAR kvinner og deres partnere; tidligere i livet, i svangerskapet og etter at barna var født. Neste mål 
var å undersøke bruk av reseptbelagte legemidler blant kvinner i OMT før og under svangerskapet. 
Siste mål var å studere svangerskapsutfall og utfall hos nyfødt etter eksponering fra buprenorfin + 
nalokson sammenlignet med metadon, buprenorfin og metadon-assistert nedtrapping. 
Materiale og metode 
Flere forskningsdesign ble brukt i denne studien; artikkel I og II er basert på et naturalistisk, 
longitudinelt, prospektivt kohort design. Studien inkluderte 38 gravide kvinner i LAR og deres 
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partnere (n=23). Artikkel III er basert på en nasjonal kohort: fra det norske fødselsregisteret og 
reseptregisteret ble 138 kvinner i LAR og 159 svangerskap inkludert. Artikkel IV er et mini-review 
basert på 7 tidligere publiserte artikler; både retrospektive og randomiserte kontrollerte studier 
(RCT).  
Resultater 
Bruk av illegale rusmidler de siste 30 dagene før begge intervjuene var lav hos kvinnene; en kvinne 
rapporterte bruk ved hvert intervju. Problematisk bruk av alkohol økte fra 0-15 % fra intervju i tredje 
trimester til intervju ett år etter at barna var født. To partnere rapporterte bruk av illegale rusmidler 
ved intervju i tredje trimester, og ett år etter at barnet var født.  Signifikant færre (p<.01) menn 
rapporterte problematisk bruk av alkohol ved andre (20 %) sammenlignet med første (38 %) intervju. 
Et flertall av kvinnene (81 %) og partnerne deres (57 %) hadde opplevd følelsesmessig og/eller fysisk, 
og/eller seksuelt misbruk tidligere i livet. De fleste kvinnene (92 %) og partnerne (91 %) hadde også 
vært plaget av en eller flere former for psykiske problemer tidligere i livet. Det var en signifikant 
reduksjon (p <.01) i symptomer på depresjon blant kvinnene fra svangerskap til seks måneder etter 
at barna var født. Fra seks måneder til to år etter var det derimot en tendens til økning i depressive 
symptomer. Blant partnerne var det en signifikant reduksjon i rapporterte psykiske problemer fra 
intervju i tredje trimester til intervju ett år etter at barna var født. De fleste gravide kvinner i LAR 
(81 %) fikk utlevert forskrevne legemidler utover LAR medikamenter på apotek under svangerskapet. 
De vanligste formene for forskrevne legemidler var antiinfektiva (48 %) og legemidler som virker på 
sentralnervesystemet (45 %). Benzodiazepiner ble brukt av 26.4 % i løpet av svangerskapet. Kun 5 % 
av kvinnene brukte antidepressiva gjennom svangerskapet. Det var signifikant flere misdannelser (p < 
.05) hos nyfødte hvis mor var ko-medisinert med legemidler med misbrukspotensial mens hun var 
gravid. Det var ingen signifikante forskjeller i svangerskapsutfall for kvinner som hadde brukt 
buprenorfin + naloxone sammenlignet kvinner som hadde brukt buprenorfin, metadon eller 
metadon-assistert nedtrapping. Barn i buprenorfin + naloxon gruppen var signifikant kortere (p < 
.001) sammenlignet med buprenorfingruppen. 
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Diskusjon og konklusjon 
De fleste kvinner i LAR i Norge og partnerne deres klarte å avstå fra å bruke illegale rusmidler både 
gjennom svangerskapet og etter at barna var født. Psykiske problemer så ut til å bli redusert fra 
slutten av svangerskapet til etter at barna var født både blant kvinnene og partnerne. Lite bruk av 
illegale rusmidler og reduksjon i psykiske problemer virker sannsynligvis positivt både for 
behandlingsutfall og for hvordan de fungerer som foreldre. Gravide kvinner i LAR bruker mer 
forskrevne medikamenter enn gravide kvinner i den generelle populasjonen. Ko-medisinering med 
medikamenter med misbrukspotensial kan øke risikoen for misdannelser hos de nyfødte og bør 
studeres nærmere. Det var ingen signifikante forskjeller i svangerskapsutfall, og kun få hos nyfødte 
ved sammenligning av buprenorfin + naloxone med buprenorfin, metadon og metadonassistert 
nedtrapping. Disse funnene bør betraktes som preliminære pga. at buprenorfin + naloxone gruppen 
var svært liten. Større studier bør undersøke mulige forskjeller i fosterets fysiske utvikling etter 
eksponering for buprenorfin + naloksone sammenlignet med buprenorfin eller metadon.  
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1.0 INTRODUCTION 
1.1 Opioid dependence and OMT 
There are approximately 1.4 million individuals with problem opioid use in Europe [1]. In Norway, the 
number of problematic opioid users is estimated to about 6900 – 12300. [2]. Individuals with opioid 
dependence are at an increased risk of morbidity and mortality [3-5]. Furthermore, they often 
experience problems with family and social networks, employment/financial legal and psychiatric 
problems [6-10]. 
 
Today several pharmacological treatment options exist for opioid dependence. Methadone was 
introduced as a treatment for opioid dependence in the 1960s in the United States [11] and in 
Norway as a national treatment program for opioid dependent individuals in 1998 [12]. Methadone 
is considered the gold standard for treatment of opioid dependence, but use of buprenorphine and 
buprenorphine + naloxone is becoming more common [12] . Whereas heroin is a short-acting opioid, 
buprenorphine and methadone are long-acting opioids with a less rewarding affect than heroin [13]. 
Methadone is a full opioid agonist, buprenorphine is a partial agonist, and exerts weaker opioid 
effect on the opioid receptors than methadone [14].  The combination drug buprenorphine + 
naloxone includes the opioid antagonist naloxone. When taken sublingually, the effect from 
buprenorphine will dominate and no clinically significant effect is exerted from naloxone. When 
injected however, the opioid antagonism cause withdrawal effect [15].  
1.2 Opioid dependence and pregnancy 
Opioid dependence in pregnant women is a major public health issue internationally and is 
associated with high costs to society and at the personal level, for the women and their children [16-
23]. Approximately one third of heroin users are women [2]; the majority of an age when they may 
have children [24]. Women with opioid dependence often come from families where one or both 
parents have had substance abuse problems [9, 25], and a majority have experienced emotional, 
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physical and/or sexual abuse at an early age [9, 26-30]. They have typically experienced low level of 
cohesion and higher levels of conflicts  in their families compared to women from similar socio-
economic backgrounds without substance abuse and/or psychiatric  problems [17, 31]. 
 
Heroin dependent women are at great risk of experiencing medical complications [32, 33]. Many get 
infections through use of needles used by others, as well as sexually transmitted diseases because of 
frequent unprotected sex [17, 34, 35]. Pregnant opioid dependent women are often poorly 
nourished and have vitamin deficiencies [17]. Abscesses, bacterial endocarditis, hepatitis and HIV is 
not uncommon [17]. Many do not get appropriate obstetric care and avoid seeking health care 
during pregnancy [36]. This may be due to the chaotic life circumstances of heroin dependent 
individuals. Previous negative experiences with the health care system, where interactions with 
health care personnel are characterized by stigmatization and blame [37] and worry about losing 
custody of their children if treatment providers  know about their substance abuse, may hinder 
women from seeking help. The life context that comes with heroin dependence may seriously affect 
birth outcomes, and with a constant search for the next fix of heroin, women are often not well 
equipped to taking care of a baby [38].  
 
Opioid Maintenance treatment (OMT) is considered the best treatment option for pregnant opioid 
dependent women [12, 39, 40]. Treatment providers that work with pregnant women in OMT should 
have special training in substance abuse (illness course and its treatment) and OMT during pregnancy 
and collaborate with specialist health care services [12, 41]. Compared to no treatment and 
medication assisted withdrawal/tapering, OMT has proved superior in regard to both maternal and 
neonatal outcomes [39, 42]. Pregnant opioid dependent women that enter OMT at an early stage of 
pregnancy, and stay in treatment, present earlier to antenatal care  and the outcomes are better for 
their neonates [43]. Once stabilized on OMT, women are also better equipped to benefit from 
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psychosocial treatment and receive help to deal with other problems associated with substance 
abuse [40]. 
 
The prevalence of psychiatric problems among pregnant women in OMT is high [28, 33, 44-46]. This 
may compromise  treatment outcomes [47] and a greater proportion of women with psychiatric 
problems test positive for illegal drugs while in OMT [48]. The increased risk of relapses may 
compromise their potential to be a dependable parent for their children. Additional psychiatric 
problems may contribute to longer hospital stay after birth [48, 49]. Furthermore, depression and 
other psychiatric problems may compromise early mother infant bonding and increase the risk of 
negative parenting behavior [50-53]. Pregnant women in OMT should be evaluated for depression 
and other psychological problems and offered appropriate treatment if needed. 
 
A large proportion of existing research on pregnancy and OMT is conducted in the U.S. where 
homelessness and poverty among opioid dependent individuals may be confounding factors [54]. In 
Norway, all inhabitants are covered by a tax-funded National Insurance System, and all have equal 
access to free health care and education. Although many pregnant opioid dependent women in 
Norway also have a low socioeconomic status [55, 56], they are not homeless or experience the same 
degree of poverty [57] as many opioid dependent individuals in the U.S. Consequently, it may be that 
pregnant women in OMT in Norway may not experience the same extent of problems as reported in 
the international literature. 
 
According to Norwegian law on substance abuse during pregnancy, women that continue to abuse 
illegal substances while pregnant may be admitted to inpatient treatment without her consent for 
parts of, or during the entire pregnancy [58]. The rationale is that this will reduce the chances of 
malformations and other negative birth outcomes that continued substance use may contribute to 
[58]. Many think these regulations are drastic and are skeptic to taking away a woman’s right to 
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make decisions in her own life. During the stay at the treatment facility the women are offered help 
to deal with both substance abuse and related problems. The women also receive help and guidance 
regarding taking care of a baby [58]. Because of major differences in health care systems and laws on 
substance abuse and pregnancy, it is important to study this population also in a Norwegian setting. 
 
1.3 The role of the partners of pregnant OMT women 
Many of the partners of pregnant OMT women have a similar history of serious substance abuse 
problems [59]. Physical violence towards women is six times more common in relationships where 
the man has substance abuse problems [60, 61], which is often the case for the partners of OMT 
women [62-65]. Female drug dependent women in abusive relationships have an increased risk of 
psychological problems and compromised treatment outcomes [66, 67]. The partners of pregnant 
OMT women may have a great influence regarding whether or not the woman will be able to stay 
substance free or relapse to substance abuse [68]. If the partners continue to abuse drugs it is 
difficult for the women to stay drug free [69]. Although partners play an important role regarding 
whether or not the women will stay drug free, they have typically not been included in studies of 
pregnant OMT women; not over time and never in a national cohort of pregnant OMT women. 
Substance abuse and psychiatric problems among pregnant OMT women and their partners may 
have an impact on how they are coping as caregivers and on whether they will keep custody over 
their children. Including the partners in treatment programs may reduce prevalence of interpersonal 
violence and drug use among opioid dependent women [70] and increase the level of support 
women receive from their partner [71]. 
 
1.4 Prescription drug use among pregnant OMT women 
Although considered to be the best treatment option for pregnant opioid dependent women [33, 39, 
49, 72, 73], OMT is not without risks, and adverse pregnancy and neonatal outcomes may occur [43, 
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74, 75]. Furthermore, due to the high prevalence of psychiatric and somatic problems among 
pregnant OMT women [4, 49], use of prescription drugs in pregnant OMT women may be high. The 
knowledge regarding the benefits from use of different prescription drugs among OMT women 
during pregnancy versus the potentially adverse effects on the fetus, is limited and incomplete. 
Pregnant OMT women are a vulnerable patient group, and knowledge on prescription drug use in 
this patient group is limited and incomplete. Many general practitioners (GPs) may have limited 
knowledge on pregnancy and co-medication among pregnant OMT women. Therefore, some women 
may not receive the medication they need. On the other hand, some pregnant OMT women may also 
receive co-medication that can be harmful for the fetus. Both under and over medication endangers 
the treatment stability of pregnant OMT women and increases the risk of relapse. It is therefore 
important to also study use of prescription drugs among pregnant OMT women. 
 
1.5 Maternal and neonatal outcomes from exposure to different OMT drugs 
Methadone has been prescribed to pregnant opioid dependent women since the late 1960s [76]. 
Although some women may  have good outcomes with methadone assisted withdrawal for opioid 
dependence [77] , most women that receive methadone-assisted  withdrawal  show worse maternal 
outcomes compared to other medicinal treatment options for opioid dependence [39]. More 
recently, use of buprenorphine to treat opioid dependence in pregnant women has increased [78-
85]. Research suggests that maternal outcomes from use of buprenorphine and methadone during 
pregnancy are similar [74, 75, 86, 87], but buprenorphine may be superior to methadone on some 
neonatal outcomes: shorter duration of NAS and shorter length of infant stay at hospital [88-91].  
Existing research on the safety of buprenorphine during pregnancy has focused on buprenorphine 
alone, Subutex® [37, 92-94] and there is a lack of research on the safety for the mother and child 
from use of buprenorphine + naloxone (Subuxone®) during pregnancy [95]. Despite a lack of research 
on its safety during pregnancy, buprenorphine + naloxone is prescribed to pregnant women many 
places in the U.S. and elsewhere. 
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1.6 Knowledge gaps 
International studies have described substance abuse and psychiatric problems among pregnant 
women in OMT. However, few of these studies have included the OMT women’s partners. 
Furthermore, there exist great differences in health care systems and other factors, such as laws 
regarding substance abuse during pregnancy in Norway and the countries where the majority of this 
research is conducted. Accordingly, the findings from international research, may not apply in a 
Norwegian setting. Therefore, it  was decided to study substance abuse and psychiatric  problems 
among pregnant OMT women  and their partners in a Norwegian context.  Moreover, it was decided 
to include the women’s partners because the partners of pregnant OMT women may contribute to 
how the women are doing in regards to continued substance use and how they are coping as 
caregivers for their children.  
 
There is limited knowledge regarding the benefits from use of different prescription drugs during 
pregnancy among OMT women versus the potentially adverse effects on the fetus. It was therefore 
decided to match information from the Norwegian prescription database and the Norwegian birth 
registry to get a more complete picture of prescription drug use among pregnant OMT women. 
 
The Norwegian guidelines for pregnant women in OMT address different medicinal treatment 
options for opioid dependence.  The guidelines suggest that buprenorphine + naloxone should not be 
used by pregnant women because there is a lack of research investigating fetal and neonatal 
outcomes from exposure to naloxone [40]. However,  despite the lack of research on the safety of 
naloxone, buprenorphine + naloxone is used to treat opioid dependent pregnant women several 
places in the U.S. and elsewhere. On this background, it was decided to compare maternal and 
neonatal outcomes from exposure to buprenorphine + naloxone to other medicinal treatments for 
opioid dependence, including methadone-assisted withdrawal.  
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2.0 OBJECTIVES 
The objectives were: 
To describe substance abuse and psychological problems among pregnant OMT women and their 
partners, to describe prescription drug use among pregnant OMT women, and to evaluate outcomes 
from exposure to buprenorphine + naloxone during pregnancy compared to other treatments 
frequently provided to pregnant opioid dependent women. 
 
The specific aims were: 
I. To investigate substance abuse and related problems in a national cohort of pregnant OMT 
women and their partners prior to, during and after pregnancy (Paper I). 
 
II. To investigate psychiatric problems among a national cohort of pregnant OMT women and 
their partners prior to, during and after pregnancy (Paper II).  
 
III.  To investigate all prescription drug use among women in OMT three months prior to, and 
during pregnancy. A main focus will be placed on prescription drugs with abuse potential (Paper III). 
 
IV.  To evaluate neonatal and maternal outcomes from exposure to buprenorphine + naloxone 
during pregnancy compared to buprenorphine alone or methadone (Paper IV).   
 
 
 
This thesis includes both published (appendix) and unpublished results.  
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3.0 MATERIAL AND METHODS 
3.1 Design 
This thesis is based on two different designs. Table 1 shows the study designs used to address each of 
the aims. 
 
Table 1. Design used to address aim I-IV 
Design Aim I Aim II Aim III Aim IV 
Cohort study X X X  
Small clinical review    X 
 
 
3.2 Sources of data  
Three different data sources were used to address aims I-IV. A national OMT cohort study from 
Norway was used to address aim I and II. The Norwegian birth registry and the Norwegian 
prescription database were used to address aim III. To address aim IV, data from seven previously 
published studies were used [39, 74, 86, 87, 96-98]. The sources used to address aim I-IV are 
presented in table 2. 
 
Table 2. Sources used to address aim I-IV. 
 Aim I Aim II Aim III Aim IV 
The national OMT cohort X X   
Norwegian prescription database   X  
The medical birth registry of Norway   X  
Data from already published papers    X 
 
3.2.1 The national OMT cohort  
The national OMT cohort includes 161 children born to 139 women from 1996 to 2009 [99]. The 
study has three parts; the first part is retrospective (n=51) and was undertaken in the period 
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between 1996- 2003 [100]. The second part is prospective (n=37) and was undertaken from 2005 to 
2007 [101]. Finally, the third study is retrospective (n=52) and was undertaken from 2004 to 2009. 
Aim I and II in this thesis were addressed using prospective data from the second part of the study. 
All regional centers and treatment facilities in Norway were asked to recruit women in OMT that 
were to give birth during January 2005 to February 2007. A research team of 3 persons; a 
psychologist, a medical doctor and a masters student contacted all OMT centers, and gave several 
lectures on risk factors related to substance abuse during pregnancy, at treatment facilities working 
with this patient group [102]. OMT centers, other drug treatment facilities, child mental health and 
child protection services received written information about the study [102]. Health care personnel 
in these settings working with pregnant OMT women were asked to forward information about the 
study to pregnant OMT women and ask for permission on behalf of the research team if they could 
contact the women about the study. Reminders were sent on a regular basis to treatment facilities 
[102]. Before being contacted by the research team, the pregnant women in OMT signed an 
informed consent form agreeing to participate in the study [102]. If the women had male partners, 
they were asked to inform their partner about the study and ask if he would consider participating. 
The partners that agreed to take part, signed informed consent before being contacted by the 
research team.  
 
3.2.2 The Medical Birth Registry of Norway (MBRN) 
The MBRN was established in 1967. All births in Norway are registered in MBRN. The registry is based 
on compulsory notification of all births and late abortions from 12 weeks of gestation. The aim of the 
registry is epidemiological surveillance of perinatal health problems and birth defects and 
surveillance of health services provided to: pregnant women, during child birth and in the neonatal 
period [103]. The notification form sent to MBRN includes name and personal identity numbers for 
the parents as well as for the child. Information about the maternal health prior to and during 
pregnancy and length of pregnancy and information about complications during pregnancy and birth 
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is recorded. Such complications include whether the baby is born alive and information about 
diagnoses and congenital abnormalities. If the mother consents, information about occupation and 
smoking habits are also registered [103]. Any additional information is included until mother and 
baby are discharged from the hospital. 
3.2.3 The Norwegian Prescription Database (NorPD) 
From January 1st 2004 it was mandatory for all pharmacies in Norway to send electronically 
information on all dispensed drugs to the NorPD. NorPD covers the entire Norwegian population 
[104] and is run by the Institute of Public Health [104, 105]. Information regarding prescription drugs 
at the individual level exists for all individuals that are dispensed prescription drugs at pharmacies. 
Data on prescription drug use among individuals currently in inpatient treatment is only registered at  
institutional level.  For all prescriptions, age and sex are registered for both patient and prescriber. 
Demographic information such as where the patient lives (municipality), specialization of the 
prescribing medical doctor and information to identify which pharmacy the drugs were dispensed at 
are also registered [106].  
 
Dispensing date and detailed drug information is included; including Anatomic Therapeutic Chemical 
(ATC) classification code and defined daily dose (DDD) dispensed.  DDD is defined  as “the assumed 
per day mean dose for a drug used for the drugs main indication for adults” [106]. To evaluate 
consumption of prescription drugs over time, both nationally and internationally, DDD may be used 
as a method to simplify and improve the comparison process [107]. All prescription drugs in Norway 
are classified according to the ATC classification system with 5 different levels. At level one the drugs 
are divided into 14 main drug groups, at level two the groups are divided into pharmacological 
/therapeutical sub-groups. At level three and four according to therapeutic/chemical/pharmacologic 
subgroups, and at level five there is the unique chemical substance code for the drug [106]. The 
evaluation of international use of a prescription drug is the basis for deciding on a drugs DDD [106]. 
Information recorded in NorPD does not include information on prescription drugs dispensed to 
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individuals at hospitals or other institutions; including receiving OMT drugs at OMT centers instead of 
pharmacies. This information is only registered at institutional level and not included in this thesis.  
3.2.4 Papers included in the small clinical review 
The articles in the clinical review were chosen on the background that they included a common 
subset of outcome measures and provided data that could be easily re-analyzed [39, 74, 86, 87, 96-
98]. The maternal outcomes were: maternal weight gain, number of prenatal obstetrical visits, drug 
screening results, use of analgesia, cesarean section, medical complications at delivery and non-
normal presentation of the fetus.  The neonatal outcomes were: treated for neonatal abstinence 
syndrome (NAS), how many days treated for NAS, total mount of morphine used to treat NAS, birth 
parameters, days at the hospital, gestational age, preterm birth and Apgar scores. Furthermore, the 
articles represented both retrospective studies and RCTs, which increase the generalizability of the 
findings. No new data were gathered but the authors of some of the studies provided standard 
deviations that were not available in their articles. The articles included were published during 2005-
2012. 
3.3 Study population 
Aim I and II: Substance abuse and psychiatric problems 
To our knowledge, all pregnant OMT women in Norway in 2005 and 2006 and their partners were 
invited to participate in the study [102]. Of the 47 OMT women located during pregnancy, 41 women 
consented to participate. Of the 6 that declined, 3 did not respond to the request about participation 
and 3 women said they did not want to participate in the study because their partners were skeptical 
to take part, and they were concerned that child protection services might be involved as a result of 
study participation [102]. Of the 41 that gave their informed consent, one woman withdrew from the 
study before the study started and two women had a miscarriage. When the study started 38 women 
were included. This is likely to equate to a response rate of 81 % of all pregnant OMT women in 
Norway during the study period. Methadone was used by 26, and buprenorphine by 12 women. Only 
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two women started OMT after conception; the majority of the women were enrolled in the OMT 
program prior to conception. [101].  On average the women had been in OMT for 2.7 years and their 
opioid dependent partners for 2.5 years.   
 
Of the 38 women, 24 had male partners. All but one of the partners signed an informed consent and 
agreed to participate in the study. Most of the partners had a similar substance abuse background, 
with several years of heroin and polydrug  abuse, as the women. However, seven men reported they 
had never used heroin and six of these seven reported they had never used illegal drugs. 
 
Aim III: Prescription drug use 
To address aim III, data from the MBRN and the NorPD were used. As regulated by Norwegian law for 
health registries linkage between MBRN and NorPD was generated through anonymous files for 
research purposes [108, 109]. Data regarding prescription drug use in all pregnant OMT women in 
Norway that were dispensed OMT drugs at a pharmacy during pregnancy, were collected for women 
that conceived from March 30th 2004, and pregnancies that ended no later than December 31st 2010. 
All singleton pregnancies during the study period were included (349 020 pregnancies). Pregnancy 
and neonatal complications are more common in twin pregnancies. Hence, twin pregnancies were 
excluded. After excluding pregnancies where the woman’s identity was unknown or she was living 
outside of Norway when she was giving birth, the number of pregnancies were 345 703.  
 
To be defined as a pregnant OMT woman, women had to be a) pregnant and b) dispensed one of the 
following OMT drugs at a pharmacy at least once during pregnancy: methadone mixture (ATC system 
code N07BC02), buprenorphine sublingual tablets (Subutex/ATC code N07BC01) or buprenorphine + 
naloxone combined sublingual tablets (Suboxone / ATC code N07BC51). After all exclusions, the 
study included 138 women with a total of 159 pregnancies. The mean age of the pregnant OMT 
women were 32 years.  
13 
 
Aim IV: Maternal and neonatal outcomes after exposure to different OMT drugs 
Seven previously published studies from 2005 to 2012 [39, 74, 86, 87, 96-98] were used to address 
aim IV. The outcome measures in the chosen papers were similar and could easily subject to re-
analysis. Debelak and colleagues conducted a retrospective chart review; 10 women that received 
buprenorphine + naloxone during pregnancy were included in the study [97]. Another retrospective 
chart  review was included  101 women that were prescribed methadone and 68 that were 
prescribed buprenorphine during pregnancy [96]. Fischer and colleagues conducted a RCT; at 
delivery there were six women in the methadone and eight in the buprenorphine condition [87]. 
Another RCT was conducted by Metz and colleagues: data on women  that underwent structured 
standard pharmacotherapy protocol, 51 women exposed to methadone and 26 exposed to 
buprenorphine were included [98]. In a third RCT, 11 women on methadone and nine on 
buprenorphine  completed the study [86]. In a fourth RCT 73 women on methadone and 58 women 
on buprenorphine completed the study [74]. Finally, a retrospective record review where 52 women 
received methadone and 28 women 7-day methadone assisted withdrawal was included [39]. See 
table 3 for an overview of the studies included.  
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Table 3. Overview of studies used to address aim IV 
 Studies included  
 Debelak et al. 
(2012) 
Czerkes et 
al. (2010) 
Fischer et 
al. (2006) 
Metz et al. 
(2011) 
Jones et al. 
(2005) 
Jones et 
al. (2010) 
Jones et al. 
(2008) 
OMT         
Buprenorphine + 
naloxone 
N=10       
Buprenorphine   N=68 N=8 N=26 N=9 N=58  
Methadone  N=101 N=6 N=51 N=11 N=73 N=52 
7-day methadone 
assisted withdrawal 
      N=28 
Data collected in the 
following country 
       
U.S. X X  X X X X 
Austria   X X  X  
Canada ‡      X  
‡ Data from the Canada  site was not included in the Jones (2010) paper because although participants were screened, they 
were not randomized. 
 
3.4 Study instruments  
Different study instruments were used to address aims I-IV. Table 4 shows an overview of which 
instruments were used at different time intervals to answer aim I-III.  
 
Table 4.  Instruments used to address aim I-III women (W) and partners (P) at different time intervals 
  Time interval Aims 
Instruments 
used 
 3 months prior 
to pregnancy 
1st 
trimester 
2nd 
trimester 
3rd 
trimester  
6 months 
after birth 
1 year after 
birth 
2 years 
after birth 
 
I 
 
II 
 
III 
 
EuropASI 
 
W 
    
X 
 
X 
 
X 
 
 
 
X 
 
X 
 
 P    X X X  X X  
 
HSCL-25 
 
W 
    
X 
 
X 
 
X 
 
X 
  
X 
 
 P    X X X   X  
            
MCMI III W    X     X  
 P    X     X  
 
DDD 
 
W 
 
X 
 
X 
 
X 
 
X 
      
X 
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The European Addiction Severity Index (EuropASI) 
EuropASI was used for aim I and II. EuropASI is a semi structured interview used both for clinical and 
research purposes [110]. The most extensive part of the interview assesses drug and alcohol use. 
Respondents are first asked how old they were when he/she started using different drugs. To count 
as age of onset, the respondents had to report using the substance in question for at least three days 
per week, or have periods with binge drinking or heavy drug use for at least two days at the time per 
week at a level where normal daily activities such as work, school and family life is compromised. 
Furthermore, the respondents are asked how many years they have used different drugs, how many 
days during the last month they have used different substances, and how the substances were used; 
orally, injected or inhaled [111]. The respondents are also asked about injecting drug use and 
overdoses.  
 
Areas often affected by drug and alcohol use are also evaluated; family and social relationships, 
employment, medical, legal and psychiatric problems. Questions regarding psychiatric problems 
include whether the respondents have been seriously depressed, experienced anxiety, 
hallucinations, problems concentrating and remembering, problems controlling violent behavior, 
attempts to suicide and more. Psychiatric problems that are directly related to substance abuse or 
abstinence should not be recorded [111] .  
 
There is a baseline and a follow-up version of the EuropASI interview. In both versions, the patient is 
asked how many of the last 30 days they have experienced problems in the different problem areas. 
This can be used to measure change in experienced problems in the different areas: substance use, 
medical and psychiatric, legal, employment/financial, family and social relations.  
 
These interviews took place in late pregnancy and most women thought it most convenient to be 
interviewed in their own home. One member of the research team would travel to the 
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woman`s/couples home. The study participants were then contacted and asked to participate in a 
structured follow-up interview by telephone one year after the baby was born.  
Hopkins Symptom Checklist 25 (HSCL -25)  
HSLC 25, which is a shorter version of HSCL-90,was used to address aim II [112, 113]. HSCL-25 is a 
short self-administered instrument that measures symptoms of psychological distress: anxiety and 
depression . Some studies also report anxiety and depression combined, Global Symptom Index (GSI), 
also called “nervousness” [9]. The respondents answer how bothered they have been about each of 
the 25 items during the last week on a 5 point scale ranging from 0 (not at all), 1 (a little bothered), 2 
(moderately bothered), 3 (quite bothered) and 4 (very bothered). The instrument is short and easy to 
administer and usually takes five minutes or less to complete. Respondents that received a score of 
1.0 or more were classified as a “case” [9].  
 
The study participants were asked to complete the HSCL-25 in the presence of the interviewer during 
third trimester of pregnancy. At six months after birth they were asked to complete and send HSCL-
25 by post. The women were also asked to complete and send HSCL-25 by post two years after birth. 
Millon Clinical Multiaxical Inventory III (MCMI III) 
MCMI III is a self-report questionnaire which measures personality traits and personality disorders 
(PDs). The instrument contains 175 true/false items which measure 14 personality profiles and 10 
clinical symptoms, for example dysthymia and anxiety [114]. The items form the basis for 24 clinical 
scales and three “modifier scales”. MCMI III and its earlier versions have been used among clinical 
populations both in Norway [9, 115-117], and internationally [118-120]. The MCMI scores are 
reported as base rate (BR) scores: transformed raw scores adjusted for gender differences. A BR 
score of 35 represents the average in the general population. In a clinical population the average BR 
score is 60. If an individual has a BR scores of 85 or above, he or she is considered to be a clinical 
case.  Only the personality scales are presented in the present thesis. The personality scales are not 
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included in the articles as we received feedback from journals that we needed to limit the results we 
presented in each article. However, as PDs may complicate treatment outcomes and parenting 
abilities, it is important that these scales are presented in this thesis [121].  
 
The women and their partners completed MCMI III in the presence of an interviewer during third 
trimester of pregnancy.  
Defined Daily Dose (DDD) 
In addition to describing prevalence of prescription drug use, it is also important to describe the 
amount of use. In the present study, defined daily dose was used to report the amount of opioids, 
benzodiazepines and z-hypnotics the pregnant women were dispensed 3 months prior to and during 
all trimesters of pregnancy. See table 5 for an overview of DDD for different benzodiazepines, z-
hypnotics and opioid analgesics. 
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Table 5. Defined Daily Dose (DDD) of benzodiazepines, z-hypnotics and opioid 
analgesics  
  ATC
 code DDD  (oral administration) 
   
Benzodiazepines  
Antiepileptics  
     Clonazepam N03AE01 8 mg 
Anxiolytics  
     Diazepam N05BA01 10 mg 
    Chlordiazepoxide N05BA02 30 mg 
     Oxazepam N05BA04 50 mg 
     Lorazepam N05BA06 2.5mg 
     Bromazepam N05BA08 10 mg 
    Clobazam N05BA09 20 mg 
     Alprazolam N05BA12 1 mg 
Hypnotics  
     Flurazepam N05CD01 30 mg 
     Nitrazepam N05CD02 5 mg 
     Flunitrazepam N05CD03 1 mg 
     Estazolam N05CD04 3 mg 
     Triazolam N05CD05 .25 mg 
     Midazolam N05CD08 15 mg 
Z-hypnotics   
    Zopiclone N05CF01 7.5 mg 
    Zolpidem N05CF02 10 mg 
    Zaleplon N05C 10 mg 
Opioid analgesics  
     Morphine N02AA01 100 mg 
     Hydromorhone N02AA03 20 mg 
     Oxycodone N02AA05 30 mg 
     Dihydrocodeine N02AA08 150mg 
     Buprenorphine N02AE01 1.2 mga 
     Codeine N02AA59 b 
a parenteral, sublingual, transdermal administration only 
b All codeine products are fixed combinations with acetaminophen. For the product that contain 400 mg 
paracetamol, one DDD will represent 1600 mg paracetamol  and 120 mg codeine. For product that contain 500 
mg paracetamol, one DDD will represent 1500 mg paracetamol  and 90 mg codeine. 
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3.5  Data analysis 
Table 6. Summary of the statistical packages and methods used to address aim I -IV.  
  Aims 
  I II III IV 
Statistical package SPSS 16.0 
SPSS 18.0 
x x  
x 
 
 SAS Version 9.2 
 
   x 
Statistical methods Crosstabs with Chi-square test 
T-test 
x x 
x 
 
x 
 
 Chi-square test   x  
 ANOVA    x 
 Logistic regression analysis    x 
 
 Aim I and II: Substance abuse and psychiatric problems 
Descriptive statistics on all problem areas in EuropASI are presented: substance use, legal, 
family/relatives, employment, psychiatric, somatic/medical. Descriptive statistics regarding 
experienced emotional, physical and sexual abuse previous in life and during the past 30 days prior to 
the interview is presented. Crosstab analyses with Fischer`s exact test were used to examine if there 
were significant changes in substance use and psychiatric problems from the interview during third  
trimester of pregnancy to the EuropASI interview one year after birth. The same procedure was 
conducted to investigate if there were changes in all the problem areas: somatic/medical, 
family/relatives, employment, and legal. Paired t-test were used to examine changes in anxiety and 
depression among the women and their male partners from last month of pregnancy to six months 
after birth; for the women also from six months to two years after birth. 
 
Aim III: Prescription drug use 
Descriptive statistics: period prevalence, means, median, interquartile range (IQR) and confidence 
intervals (CI), regarding prescription drug use prior to and during pregnancy in pregnant OMT women 
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are presented. CIs for proportions were calculated using a corrected version of the score [122]. 
Period prevalence was measured in 3 month intervals: 3 months prior to conception and every 
trimester. Women that were dispensed a drug at least once during a 3-month time interval was 
registered as using that drug during that time period. The effect of co-medication with opioid 
analgesics, benzodiazepines or z-hypnotics on maternal and neonatal outcomes were examined using 
bivariate analysis as appropriate: chi square test or t-test.  
 
Aim IV: Maternal and neonatal outcomes after exposure to different OMT drugs 
Summary statistics were collected for the articles used to address aim IV [39, 74, 86, 87, 96-98]: 
means and standard deviations for continuous variables and frequencies for binary variables. Firth`s  
penalized maximum likelihood approach was utilized to conduct tests of significance for the logistic 
regression analyses [123] because some of the studies that did yield data had very small or zero 
frequencies. One-way analysis of variance was used to analyze the continuous outcome data [124]. 
Three single degrees of freedom were created for each outcome measure to address the three 
questions posed in the present study. 
3.6 Ethics 
Aim I and II: Substance abuse and psychiatric problems 
The protocol was approved by the Regional Ethics Committee. 
 
Aim III: Prescription drug use 
The Norwegian Prescription Database and the Medical Birth Register of Norway was linked by using a 
pseudonymous personal identification number, according to regulations in Norwegian law for health 
registers. The research files did not contain any personal identification, and keys for matching were 
kept separately from the research team by a third party (Statistics Norway). Informed consent was 
not required for this study. 
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Aim IV: Maternal and neonatal outcomes after exposure to different OMT drugs 
Additional approval from official bodies was not necessary since already published papers were used 
to address aim IV [39, 74, 86, 87, 96-98]. 
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4.0 RESULTS 
4.1 Aim I: Substance abuse and related problems   
Both the women, and the partners that had a substance abuse background, had used heroin for on 
average eight years. Women reported an  average of 10 years and their partners 13 years with poly-
drug abuse.  
 
Only one woman reported using illegal substances during the last 30 days prior to the interview being 
conducted in the final month of pregnancy: heroin and amphetamine. Another woman reported 
using cannabis during the last 30 days prior to the interview being conducted one year after the 
children were born. Two of the partners used illegal substances during the 30 days prior to the 
interview conducted in the third trimester of pregnancy; other opiates than heroin or OMT 
medications, and cannabis. One of these men also reported using cannabis prior to the interview 
conducted one year after the birth. 
 
No women reported problem drinking in the last 30 days prior to the interview conducted in the last 
month of pregnancy. However, five reported problem drinking prior to the interview at the interview 
conducted one year after the birth. The partners reported significantly less (p < .01) problem drinking 
at the interview conducted one year after birth (20 %) than at the interview during the third 
trimester of pregnancy (38 %). 
 
Somatic/medical problems were significantly (p < .05) reduced among the women from third 
trimester to one year after (41-34 %). No prostitution or criminal activity was reported at any time 
interval. More women reported problems with families and relatives (8-20 %) and more partners 
reported problems with others (4-16 %) one year after the child was born. Reported problems with 
unemployment were relatively stable for both the women (3 %) and their partners (13-10 %).   
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4.2 Aim II: Psychiatric problems  
A majority of the women (81 %) and the partners (57 %) had experienced emotional and/or physical 
and/or sexual abuse earlier in life. Two of the women reported  emotional abuse, one of these also 
reported physical abuse, 30 days prior to the interview conducted during the last month of 
pregnancy. One of these women was single. The other had an opioid dependent partner; he was the 
only partner who reported  any form of abuse, physical abuse, during the same time interval. 
 
A majority of women (92 %) and their partners (91 %) reported that they had experienced one or 
more forms of psychiatric problems earlier in life. More partners with substance abuse history 
reported psychological problems (94 %) compared to partners without such a background (71 %). 
The most common psychological problems among the women both during pregnancy and one year 
after the child was born, were problems concentrating, understanding and remembering (41 % and 
32 %), followed by serious anxiety (15 % and 14 %) and depression: (8 % and 0 %). Serious thoughts 
of suicide were reported by two women and two partners during pregnancy. One year after the child 
was born however, there no reports of thoughts of suicide among the women or their partners. 
There were no reports of hallucinations or problems controlling violent behavior among the women 
or their partners at any of the time intervals. There were no differences in report of psychiatric 
problems among women with and without partners. More women without daily care of children 
born prior to joining the study reported psychiatric problems (75 %), compared to women that had 
daily care of their previously born children (20 %). There was a significant decrease (p < .05) in 
psychiatric problems among the partners from interview in third trimester (42 %) to one year after 
the children were born (30 %). 
 
The GSI showed  that 36 %, 12 % and 19 % nervousness cases among the women during the last 
seven days prior to the interviews during third trimester, six months and two years after birth 
respectively. Among the partners, there were 4% and 8 % nervousness cases  prior to the interview 
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during third trimester and 6 months after the children were born  respectively. Among the women 
there was a significant reduction (p < .01) in depressive symptoms from last month of pregnancy to 
six months after giving birth, and the number of depressive “cases” were reduced from 36-10 %. 
From six months to two years after birth there was a tendency towards an increase in depressive 
symptoms among the women; both on average (0.54 – 0.77) and “cases” (10-26 %). There was a 
reduction in both average anxiety symptoms score (0.44 – 0.33) and percentages of “cases” (9-4 %) 
among the partners from third trimester to six months after, whereas depressive cases increased 
from 4-8 %. 
 
According to MCMI-III, fourteen (41 %) women and eight (33 %) partners had one or more 
personality disorders (PDs). The most common PDs among women were depressive (21 %), histrionic 
(12 %) and masochistic (12 %). Among the partners depressive (21 %) and antisocial (13 %) PD were 
most common (table 7). 
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Table 7. Prevalence of personality disorders among the OMT women and 
 their partners, measured in the last month of pregnancy, MCMI III. 
Personality disorders OMT Women  
(n=34)  
N (%) 
Partners  
(n=24)  
N (%) 
Schizoid - - 
Avoidant 2 (6) 1 (4) 
Depressive 7 (21) 5 (21) 
Dependent 3 (9) 2 (8) 
Histrionic 4 (12) - 
Narcissistic 2 (6) 2 (8) 
Antisocial 3 (9) 3 (13) 
Sadistic  1 (3) - 
Compulsive - - 
Negativistic 1 (3) 2 (8) 
Masochistic 4 (12) 1 (4) 
Schizotypal - 1 (4) 
Borderline 2 (6) 2 (8) 
Paranoid - 1 (4) 
 
4.3 Aim III: Prescription drug use 
During pregnancy, 51 % of women were dispensed methadone, 49 % buprenorphine and 10 % 
buprenorphine + naloxone. All the women that used buprenorphine + naloxone switched to 
buprenorphine alone during pregnancy. 
 
Excluding OMT drugs, 81 % of women were dispensed prescription drugs during pregnancy and 69 % 
during the 3 months prior to pregnancy. The proportion of women that were dispensed drugs was 
higher both prior to pregnancy, and during all trimesters, than among pregnant women in the 
general population [108]. In particular, use of antiinfectives (48 %) and drugs acting on the central 
nervous system (45 %) were higher among pregnant women in OMT (Table 8).  
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Table 8. Number, prevalence (%) and confidence interval (CI) of pregnancies in Opioid Maintenance Treatment in 
Norway (2004-2010) where the women were dispensed prescription drugs 3 months prior to and during pregnancy 
(n=159) compared to prescription drugs dispensed to pregnant women in the general population in 2004-2006 
(n=106 329).  
Drug groups  (ATC a group) 
 3 months 
before to 
pregnancy 
1. trimester 2. trimester 3. trimester Entire pregnancy  (40 weeks) 
  N %  CI [95] N %  CI [95]    N %  CI [95] N %  CI [95] N %  CI [95] 
Alimentary tract and metabolism (A) 6 4 [2-8] 21 13 [9-20 ] 12 8 [4-13] 7 4 [2-9] 30 19 [13-26] 
  2.9 %‡  4.4 % ‡  2.7 % ‡  2.6 % ‡   
Blood and blood forming organs (B) 7 4 [2-9] 10 6[3-12] 13 8 [5-14] 9 6 [3-11] 21 13 [9-20] 
  0,8 % ‡  2.3 % ‡  2.2 % ‡  2.5 % ‡   
Cardiovascular system (C)  7 4 [2-9] 7 4 [2-9] 2 1 [0-5] 6 4 [2-8] 13 8 [5-14] 
  0.9 % ‡  0.7 % ‡  0.7 % ‡  1.8 % ‡   
Dermatologicals (D) 12 8 [4-13] 9 6 [3-11] 8 5 [2-10] 7 4 [2-9] 18 11 [7-18] 
  4.2 % ‡  3.2 % ‡  3.4 % ‡  2.0 % ‡   
Genitourinary system and sex 
hormones (G) 15 9 [6-15] 6 4 [2-8] 6 4 [2-8] 0 0 [0] 12 8 [4-13] 
  12.7 % ‡  6.1 % ‡  1.4 % ‡  1.0 % ‡   
Systemic hormonal preparations 
excl. sex hormones and insulin's ( H) 10 6 [3-12] 4 3 [1-7] 9 6 [3-11] 7 4 [2-9] 11 7 [4-12] 
  3.2 % ‡  2.0 % ‡  1.8 % ‡  1.9 % ‡   
Antiinfectives for systemic use (J) 36 23 [17-30] 30 19 [13-26] 40 25 [19-33] 31 19 [14-27] 77 48 [40-56] 
  11.1 % ‡  10.0 % ‡  12.2 % ‡  13.0 % ‡   
Antioneoplastic and 
immunomodulating  agents (L) 2 1 [0-5] 1 0 [0-4] 0 0 [0] 0 0 [0] 1 0 [0-4] 
  0.7 % ‡  0.1 % ‡  0‡  0‡   
Muscoskeltal system (M) 18 11 [7-18] 9 6 [3-11] 3 2 [0-6] 0 0 [0] 12 8 [4-13] 
  6.0 % ‡  2.3 % ‡  0.4 % ‡  0.2 % ‡   
Central nervous system (N)  excl. 
drugs used in opioid dependence 71 45 [37-53] 59 37 [30-45] 41 26 [19-33] 21 13 [9-20] 71 45 [37-53] 
  7.0 % ‡  5.0 % ‡  2.9 % ‡  2.8 % ‡   
Antiparasitic products, incecticides 
and repellents (P) 4 3 [1-7] 2 1 [0-5] 0 0 [0] 0 0 [0] 2 1 [0-5] 
  1.0 % ‡  0.4 % ‡  0.2 % ‡  0.1 % ‡   
Respiratory system (R)  29 18 [13-25] 21 13 [9-20] 20 13 [8-19] 19 6 [3-11] 40 25 [19-33] 
  8.4 % ‡  7.9 % ‡  7.4 % ‡  7.1 % ‡   
Sensory organs  and various (S+V) 7 4 [2-9] 4 3 [1-7] 2 1 [0-5] 6 4 [2-8] 11 7 [4-12] 
  3.4 %‡  2.6 %‡  2.9 %‡  2.8 %‡   
Total 110 69 [61-76] 96 60 [52-68] 100 63 [55-70] 74 47 [39-55] 129 81 [74-87] 
  39 %‡  33 %‡  29 %‡  29 %‡  57 %‡ 
a ATC = Anatomical Therapeutic Chemical  
 ‡Data (prevalence %) on use of prescription drugs among pregnant women (n=106 329) in the general Norwegian population (2004-
2006) from Engeland and colleagues [108]. 
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Benzodiazepines (anti-epileptics, anxiolytics or hypnotics) were used by 26.4 % (95 % CI 20-34) of the 
women during the entire pregnancy. Anxiolytics were the benzodiazepine group used most often 
during pregnancy (21 %). All groups of benzodiazepines were reduced from prior to pregnancy to the 
last trimester of pregnancy. During pregnancy 15 % of women were dispensed opioid analgesics. Use 
was reduced from 11 % during the three months prior to pregnancy to 3 % during the last trimester.  
 
Women that were dispensed opioids, benzodiazepines and z-hypnotics often received these 
prescriptions from another GP than the GP prescribing OMT drugs. This applied for 17 of 30 women 
that received opioid analgesics, six of eight that received benzodiazepine antiepileptics, 20 of 42 that 
were dispensed benzodiazepine anxiolytics, seven of eight that received benzodiazepine hypnotics 
and in 11 of 16 that were dispensed z-hypnotics.  
 
The women that received hypnotics received high doses during pregnancy: median 145 DDD. The 
doses of strong opioids were also relatively high; median 85 DDD, as were the doses for z-hypnotics; 
median 80 DDD.  
 
Only 5 % of the women were dispensed antidepressants during pregnancy. Use of non-selective 
monoamine reuptake inhibitors and selective serotonin reuptake inhibitors were the same (2 %) 
during pregnancy. Use of other antidepressants was 1 % during pregnancy.  
 
Significantly more (p < .05) neonates were born with malformations if their mother was co-
medicated with drugs with abuse potential.  
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4.4 Aim IV: Maternal and neonatal outcomes from exposure to different OMT drugs 
There were no significant differences in any of the maternal outcomes measured; number of 
prenatal obstetrical visits, maternal weight gain, medical complications at delivery,  cesarean section, 
use of analgesia at delivery,  drug screening results and non-normal presentation of the fetus, 
between the group of women exposed to buprenorphine + naloxone compared to women exposed 
to buprenorphine alone, methadone, or 7-day methadone-assisted withdrawal. The neonates in the 
buprenorphine + naloxone group had significantly higher (p < .05) head circumference compared to 
neonates in the methadone-assisted withdrawal group. Neonates in the buprenorphine + naloxone 
group were significantly shorter (p < .001) than neonates in the buprenorphine group. The Apgar 
scores at 5 minutes were significantly lower (p < .05) in the buprenorphine + naloxone group 
compared to the buprenorphine group. No significant differences in neonatal outcomes from 
exposure to buprenorphine + naloxone compared to buprenorphine, methadone or methadone 
assisted withdrawal were observed in regards to whether the neonates needed to be treated for 
NAS, amount of morphine needed to treat NAS, days of infant hospital stay, birth weight, pre-term 
birth or gestational age at delivery. 
4.5 Brief summary of main findings 
Use of illegal substances during pregnancy was low and further reduced one year after the children 
were born among both the women (3-0 %) and their partners (8-5 %). More women (0-15 %) and 
fewer partners (30-16 %) reported drinking alcohol one year after the children were born. 
 
There was a significant reduction in depressive symptoms from pregnancy to six months after among 
the women (p<.01), but a tendency for increase in depressive symptoms from six months to two 
years after birth. There was a significant decrease (p< .05) in psychiatric problems among the 
partners from pregnancy to one year after the children were born. 
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Pregnant women in OMT used more prescription drugs than pregnant women in the general 
population. Antiinfectives and drugs acting on the central nervous system were the most commonly 
used drug groups. Use of benzodiazepines was high, but was reduced from prior to pregnancy to the 
third trimester of pregnancy. Use of antidepressants was low and malformations were significantly 
more common among children born to pregnant women that were co- medicated with drugs with 
abuse potential.  
 
There were no significant differences in maternal outcomes from use of buprenorphine + naloxone 
during pregnancy compared to buprenorphine, methadone and methadone assisted withdrawal. 
Neonates in the buprenorphine + naloxone group  were significantly shorter at birth, compared to 
the buprenorphine alone group.  
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5.0 DISCUSSION 
5.1 Methodological considerations 
5.1.1 Type 2 error 
Research on small patient groups is challenging. Norway only has 5 million inhabitants and the 
number of pregnant women in OMT every year is limited. Some challenges with small sample sizes 
are that existing differences are not detected because the sample size is too small to show these 
differences. These concerns apply for all the studies included in this thesis. The national OMT cohort 
comprises of only 38 women and their 23 partners, the registry study consists of 159 pregnancies in 
138 women in OMT, and all the studies included in the clinical mini review are small or relatively 
small. In paper IV, the buprenorphine + naloxone sample was very small, and  it may be that existing 
differences may not have been detected  are due to lack in power. In the U.S., pregnancy and opioid 
dependence is more common and recruitment for larger studies is more likely. However, to achieve a 
large sample size in a Norwegian setting would take many years. To estimate whether co-medication 
with drugs with abuse potential increase the risk of important neonatal outcomes we would need:  A 
statistical power of at least 0.8 at an alpha level of 0.05 is needed to detect a 10 % increase in NAS, 
200 g lower birth weight and a doubling in proportion of preterm birth, in a cohort size of 700 
women, where about 1/3 receive co-medication. 
5.1.2 Selection bias 
Selection bias has been described as systematic errors that result from selective losses of individuals 
prior to the data analysis, or from the way individuals are selected into the study [125].  
 
All pregnant women known to be in OMT in Norway were invited to participate in the national OMT 
cohort study. The majority of women (81 %) agreed to participate. The recruitment was entrusted to 
treatment providers in contact with OMT patients in Norway. Due to confidentiality reasons, we do 
not know whether or not the women that chose vs. chose not to participate differ significantly. 
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The women and the partners that did not participate in the six months, one and two year follow up 
may be different from those that wanted to continue to contribute to the study.   
 
Selection bias may also have occurred when addressing aim III. The prescription database contains 
information on all prescription drugs dispensed to all individuals outside institutions. However, OMT 
dispensed at OMT centers or other treatment facilities, is not registered in the prescription database 
at an individual level but at an institution level. It has become increasingly common that OMT 
patients receive prescriptions for buprenorphine or methadone by a GP and are dispensed the 
medications at a pharmacy. In 2004, about 60 of OMT patients received their medication at 
pharmacies, whereas in 2010, close to 100 % of OMT patients in Norway were dispensed OMT drugs 
at a pharmacy [126]. The pregnant opioid dependent women that receive buprenorphine or 
methadone at OMT centers may differ in significant ways from women that are prescribed OMT 
drugs from their GP. To receive OMT outside specialist treatment centers, patients need to show 
compliance with the treatment plan and adequate cooperation [12, 40]. If patients continue to use 
illegal substances while they receive OMT  from  GPs in the primary health care service, their 
treatment plan will be moved to the specialist health care services [12]. This may indicate that the 
women that receive OMT outside institutions are healthier and/or are more stable than women that 
daily receive OMT at OMT centers.  
 
The selection of studies used to answer aim IV may have affected the results. The studies were 
chosen because we wanted to include studies with different study designs and studies that reported 
the same maternal and neonatal outcomes. However, the exclusion criteria in each study differed, 
loss of individuals prior to the data analysis in the studies varied, and the way individuals were 
selected differed [39, 74, 86, 87, 96-98].  
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5.1.3 Information bias 
Information bias has been defined as systematic error that occurs when the information collected 
from or about study subjects is erroneous or misclassified [127]. Study subjects in the National OMT 
cohort study may have had recall biases. The women know that many children that are exposed to 
OMT in utero are born with NAS and may be especially aware of other potential risk factors such as 
continued substance abuse, use of prescription drugs and psychiatric problems. This may have 
affected answers at the EuropASI interview one year after the children were born. Mothers whose 
children were born with NAS may remember all potential risk factors better than mothers whose 
babies were not born with NAS. This recall discrepancy is called maternal recall bias [127].  
 
The data collection procedure at the different time intervals differed. The EuropASI and HSCL-25 that 
were completed during third trimester were face to face interviews and self-completing 
questionnaire with the interviewer present, respectively. At the follow-up data collection points, the 
EuropASI was conducted as a telephone interview and HSCL-25 was sent via mail. The changes in 
data collection procedure may have affected how women and their partners responded to the 
interview questions and/or the way the questionnaire was completed. Furthermore, social 
desirability responding is more common when interviews are conducted in person [128]. 
 
Data used to address aim III was collected from MBRN and NorPD. Data on dispensed drugs were 
registered at pharmacies so it can be assumed that information bias was low. However, the ATC and 
DDDs were used to describe prevalence and amount of different prescription drugs used. NorPD was 
established in 2004, and during the first year 6 % of the prescriptions drugs dispensed had invalid 
personal identification numbers. This proportion had been reduced to 2 % per year by 2007 [105]. 
Prescriptions with invalid personal identification may have contributed to a slightly lower prevalence 
figure than the accurate number of women in OMT that receive prescription drugs. For the same 
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reason, it may be that the amount of opioids, benzodiazepines and z-hypnotics presented in this 
study is slightly lower than what is accurate.  
 
5.1.4 Confounding 
Confounding has been defined as “the confusion, or mixing, of effects” [127]. This definition suggests 
that effects of one or more variables are mixed with the effects of exposure, which leads to a bias 
[127]. 
 
The present study investigated if there were differences in neonatal outcomes in children born to 
women that were dispensed drugs with abuse potential during pregnancy compared to women that 
did not receive such co-medication. Because our research data file did not include necessary 
information on confounding variables to conduct multivariate analyses, only bivariate analyses were 
performed. Therefore, we do not know whether the significantly higher prevalence of malformations 
in neonates whose mothers had received co-medication with abuse potential was due to the co-
medication or confounding variables such as smoking, continued substance abuse or poor nutrition 
etc. Confounding by indication is a problem that arise because those that take a drug  differ from 
those who do not take this drug [127]. The women who received such co-medication may have 
worse health and thus have higher risk of adverse pregnancy and neonatal outcomes.  
 
We lack background information about potential confounding factors regarding the women in some 
of the studies used to answer aim IV. Therefore, we do not know how comparable the women in the 
retrospective studies are to the women in the RCT studies. Confounding by indication may also be an 
issue: opioid dependent women that use buprenorphine + naloxone may differ from women that use 
buprenorphine or methadone. The retrospective study on buprenorphine + naloxone during 
pregnancy does not offer information about disease history of the women however, and we can only 
speculate how comparable they are to the women using methadone or buprenorphine.  
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5.1.5 Instruments used 
The validity and reliability of EuropASI are reported as satisfactory by some [129], whereas others are 
more critical to the instrument [130]. However, most of the critique raised towards the instrument is 
related to the composite scores, which were not used in the present study. One of the problems 
raised is related to lack of sensitivity in weighing the scores [131]. For example, for substance abuse 
the composite score is not sensitive to low use of substances such as heroin. Even with reports on 
low use of heroin, any use of such a substance is a problem. Low use of heroin should be weighed 
differently than low use of some other substances [131].  
 
The present study used problems in the last 30 days instead of composite scores to measure change 
in substance abuse and related areas. It may be that the relatively short timeframe is not 
representative of the usual situation for the respondents [9]; for example it is unlikely that the 
interview conducted during the last month of the pregnancy was not representative in some aspects, 
especially for the women that may have experienced more physical problems because they were 
carrying a baby.  
 
The validity of the terms severe depression and anxiety may be questioned. Even though the 
EuropASI manual offers description of symptoms of severe depression and anxiety, these are not 
very specific. Whether or not the respondents will describe their symptoms as severe depends on 
their personality and also on how the interviewer phrases his or her questions[111]. Furthermore, 
the symptoms should be present also when the person is not under the influence of alcohol or drugs 
[111].  
 
HSCL-25 is considered to be a reliable and valid measure of symptoms of anxiety and depression 
[132]. If items for depression and/or anxiety were missing at any of the time intervals for any of the 
respondents, data on depression and/or anxiety were excluded for that respondent at that time 
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interval. This decision was reached on the background that we had no control over what their answer 
might have been and it was considered inappropriate to calculate a score where items were missing. 
HSCL-25 has been criticized for not separating well enough between anxiety and depression [9]. On 
the other hand, it has been argued that these symptoms often occur concomitantly  [133] and some 
studies report GSI, anxiety and depression combined, as an expression of “general nervousness” [9]. 
Despite criticism towards HSCL-25, the instrument may give a more accurate picture of symptoms of 
depression and anxiety than EuropASI [9], which only asks one question regarding anxiety and 
depression respectively. There also exist a 4-point SCL scale, where a common cut-off is 1.75 [134]. In 
the present study, however, we chose to use the 5-point HSCL-25 version, and a cut-off for 
psychiatric case on 1.0. This version was chosen to more easily compare findings with a previous  
study on opioid dependent individuals in Norway, which used a 5-point HSCL-scale and  [9].  
 
It may be questioned whether  self-completion forms  such as MCMI III are as suitable to measure 
personality disorders as personal structured interviews. Because of the different approach, self-
completion instruments and interviews are likely to map different dimensions of the same 
personality disorder or  even different PDs  [135, 136]. However, such differences appear also 
between different personal structured interviews, such as SCID and MMPI [136].The decision to use 
MCMI III to evaluate PDs was reached on the background of practical considerations, such as lack of 
resources to conduct time consuming clinical interviews.  
 
There exist some limitations with measuring prescription drug use during a month with DDDs. Firstly, 
looking at opioids as one group may be problematic, since one DDD of weak opioids, such as codeine, 
would then count similarly as one DDD of a stronger opioid, such as morphine.  To avoid this 
problem, DDDs were grouped into strong and weak opioids in the present study. Secondly, it is not 
uncommon for prescribers to prescribe opioid analgesics to be used “as agreed with GP” or “as 
needed”. Therefore, amount used per day may vary considerably according to level of pain on 
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different days [137]. Accordingly, DDDs may not give a correct picture of amount of opioids 
consumed by pregnant women in OMT. 
5.1.6 Classifications and labeling 
If the respondents answered yes to ANY psychiatric problems or having used ANY illegal or legal 
substances in the past 30 days prior to the EuropASI interviews, it was classified as having reported 
psychiatric problems with legal or illegal substances. For psychiatric problems, this classification led 
to high prevalence of psychiatric problems according to EuropASI. On the HSCL-25 (range from 0-4) a 
score above 1  was the cut-off point for a possible “case” with depression and/or anxiety problems 
[9]. 
5.1.7 External validity 
External validity or generalization is the assumption that the results of the study also apply outside 
that population [138].  
 
Although a national cohort of pregnant OMT women were used to answer aim I and II, these results 
may be more easily generalized to Nordic countries and countries with similar health care systems. 
The Norwegian health care system differs greatly from many  countries. Furthermore, the strict laws 
in Norway regarding substance abuse during pregnancy greatly differ from most other countries [58]. 
In a Norwegian setting however, the results should be considered representative for pregnant OMT 
women and their partners.  
 
Regarding use of prescription drugs prior to and during pregnancy (Aim III), OMT women in other 
countries probably experience similar health problems as OMT women in Norway. Therefore, 
antiinfectives and drugs acting on the central nervous system may also be the most used prescription 
drug groups among pregnant OMT women in other countries.  
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The majority of the studies included to address aim IV were from the U.S. We know that extreme 
poverty and homelessness is common among substance dependent pregnant women in the U.S. 
[139]. These factors are additional stressors that may have a negative influence on maternal and 
neonatal outcomes. Furthermore, several of the studies were retrospective and we lack background 
information about the women in these studies. Therefore, we do not know if the women included 
differ significantly from pregnant OMT women in general. 
5.1.8 Strengths 
The data in the national OMT cohort is unique. It is the first national cohort that includes the 
partners of pregnant OMT women and follow their families over time. 
 
To our knowledge, no previous study has described all prescription drug use in a six year national 
cohort (2004-2010) of pregnant OMT women. The unique personal identity number assigned to all 
individuals in Norway, and the population based registries on birth, prescriptions and more, provide 
high quality linkages between registries in Norway. These data sources offer opportunities to answer 
important questions about prescription drug use among pregnant women in OMT and maternal and 
neonatal outcomes after exposure to different prescription drugs during pregnancy. Studying 
dispensed, rather than prescribed prescription drugs has an advantage since some individuals may 
not comply to treatment and fail to go to the pharmacy to hand in the prescription [140]. 
Consequently, the prescribed drug may not be dispensed. Following all patients to control that they 
actually ingest the prescription drugs is not an option. Therefore, studying prescription drugs that are 
dispensed is probably the closest we can get to accurately describe use of prescription drugs in a 
patient population [137].  
 
As far as we know, no previous studies have compared maternal and neonatal outcomes after 
exposure to buprenorphine + naloxone vs. buprenorphine vs. methadone  and methadone assisted 
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withdrawal during pregnancy. The findings offer an important contribution to the literature of 
medicinal treatment for opioid dependence during pregnancy. 
5.2 Discussion of results 
5.2.1 Aim I: Substance abuse  
The study showed that substance abuse was low both during interview in the third trimester and one 
year after birth both among the women and their partners.  
 
The women had a long history of heroin and poly-drug use prior to joining OMT.  However, illegal 
substance use remained low from the last month of pregnancy to one year after child birth among 
the women in OMT. This applied also for problems that are often related to substance abuse; legal, 
psychiatric, financial as well as problems with social relations. Medical /somatic problems were 
significantly reduced among the women from third trimester to one year after birth.  
 
Low use of illegal substances is positive for the women’s parenting and care giving abilities. A 
majority of the children were  still living with their mothers when they were two and a half years old,  
only three children lived in foster homes  [102]. One child was placed directly in foster care after 
being born, but moved back to the parents after one year. One child was placed in permanent foster 
care one month after being born, and two children were placed in foster care when they were aged 
between one and two and a half years old [102]. This percentage is low compared to a study of 
women with substance abuse problems in Finland, where 38 % of children were in “out of home 
care” when up until they were two years old [18].  
 
On the other hand, there was an increase in problem drinking among the women from pregnancy to 
one year after. No women reported drinking the 30 days prior to the interview during pregnancy, 
whereas 15 % reported problem drinking one year later. This may suggest that women are having a 
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difficult time, and the increased alcohol consumption needs to be addressed. Parental alcohol abuse 
may have severe consequences for the children [141, 142]. Furthermore, individuals that are opioid 
dependent and have additional alcohol problems may have more severe dependence problems in 
general and are at increased risk of poor treatment outcomes [143, 144]. Moreover, the prevalence 
of psychiatric problems among opioid dependent women with co-occurring alcohol problems is also 
significantly higher compared to women with only opioid dependence [143]. Relapses to drug abuse 
after birth is common [91], and these findings underscore the importance of following pregnant OMT 
women and their families closely for a longer time period after birth. The Norwegian guidelines for 
pregnant women in OTM suggest that these families should be offered close follow-up until the child 
starts school [40]. This may contribute to better treatment outcome for the parents and improved 
developing outcomes for the child in a secure care giving situation [40]. 
 
The majority of the partners of the national cohort of pregnant OMT women in Norway had a similar 
substance abuse background as the women. However, seven of the partners had never used heroin 
and six of  the seven had never used illegal drugs. The other two thirds had on average eight years of 
heroin and 13 years of poly-drug abuse behind them. Studies show that if the partner relapses to 
substance use again this is likely to subsequently increase the chance of a relapse in the woman [71, 
145]. However, in the present study, use of illegal substances was low both during 3 trimester and 
one year after child birth among the partners. 
 
 Becoming a parent is an important life event that may contribute to additional motivation to stay 
drug free. The parents may be less likely to experience a relapse and may be motivated to make an 
extra effort to deal with their own problems, because they know this would also benefit their 
children. From an economic perspective it is beneficial that the OMT women and their partners stay 
in treatment for a longer period since relapse to illicit substance use, entry into new treatment and 
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increased dependence on unemployment and disability pensions are expensive. What the best 
solution for the child, the parents and society is, has to be carefully evaluated in every case [9].  
 5.2.2 Aim II: Psychiatric problems 
The prevalence of psychiatric problems among the women and their partners was low both during 
third trimester of pregnancy and one year after the children were born.  The prevalence of 
personality disorders however, was substantial among the women and their partners alike.  
 
The majority of the women and their partners had experienced one or more forms of abuse earlier in 
life: emotional and/or physical and/or sexual. Lifetime emotional and physical abuse were higher in 
the present study than what was reported in previous Norwegian and international literature [26, 65, 
139, 146]. Reported lifetime sexual abuse among the women was higher than in  some U.S studies 
[65, 139] whereas both sexual abuse and emotional abuse were lower than in other studies from the 
U.S, both in a lifetime perspective and during pregnancy [26, 147]. Previous studies have shown that 
substance dependent women are at greater risk of experiencing intimate partner violence [148, 149] 
and a study from the U.S. reported that 38 % of men in methadone maintenance were violent 
towards their intimate partner during the last six months [150]. In comparison, the prevalence of 
physical abuse reported among the women during last 30 days prior to interview in third trimester 
was very low. These findings may indicate that when both people in the relationship have been in 
treatment for a while, as was the case for the majority of the women and their partners in paper II, 
these problems may be greatly reduced or no longer experienced at all. It is therefore important to 
include the partners of pregnant OMT women in treatment and research, since they may have a 
great impact on treatment retention and how the woman will cope as a parent [59, 66, 67, 71].  
 
Except for problems concentrating, understanding and remembering, reported psychiatric problems 
was low among pregnant OMT women and their partners during pregnancy compared to 
international literature [44, 48, 49]; and was further reduced after the children were born. One 
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possible explanation to why there was a low prevalence of psychiatric problems among the women 
and their partners, compared to previous studies, is that they had been in OMT on average about 
two and a half years prior to joining the study. In most previous studies women start OMT only when 
they discover they are pregnant, [39, 86, 151]. At that point they are probably less stable than what 
is the case in the present study [152].  There were fewer nervousness cases among the  women in 
paper II during third trimester (35 %), six months (12 %) and two years  (19 %) after birth,  compared 
to  nervous “cases” among opioid dependent individuals (55 %) at intake to methadone treatment in  
a Norwegian study [9],  
 
About two out of every fifth OMT woman and one third of the men had one or more PDs. Previous 
studies have shown that victims of childhood abuse are at increased risk for developing PDs in 
addition to being more prone to depression, anxiety, drug and alcohol dependence [119, 153]. Drug 
dependent individuals with co-occurring PDs are at increased risk of negative treatment outcomes 
[116, 121, 145, 154].  
 
Compared to previous international and Norwegian studies on opioid dependent individuals, the 
prevalence of PDs in this cohort of OMT women and their partners is low. In a Canadian study, 77 % 
of OMT patients had one or more PDs [120] and a Norwegian study reported PDs in three of four 
individuals [9]. Antisocial and borderline PD are often the most common PDs in substance dependent 
populations [9]. This was not the case in the present study. Depressive, histrionic and masochistic 
PDs were most common among the women. Among the partners, depressive PD was most common, 
followed by antisocial. PDs are also related to lower functioning in interpersonal domains, including 
negative parenting behavior which may severely affect the parent-child interaction [155, 156]. 
Thorough psychiatric evaluations should be conducted in pregnant OMT women, also checking for 
PDs. Pregnant OMT women with co-occurring PDs and/or psychiatric problems should be followed 
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closely and offered additional help to increase their chances to cope well in their parenting role 
[156].  
5.2.3  Aim III: Prescription drug use  
In paper I, 8 % of the OMT women reported using benzodiazepines during the past 30 days prior to 
the interview undertaken in the third trimester. In paper III use of benzodiazepines was lower (4 %) 
even though this was over three months: the entire third trimester.  Although different data 
collection procedures were used, there is probably some overlap between the women included in 
paper III for the time period 2005-2006, and the women included paper I. However, some of the 
women in paper I probably received methadone or buprenorphine at OMT centers or other 
treatment facilities for parts of, or the entire pregnancy. Information on prescription drug use among 
women that receive methadone or buprenorphine at OMT centers or other treatment facilities for 
the entire pregnancy is not included in NorPD at an individual level, and therefore not included in 
paper III.  Therefore, it may be that the reports on use of benzodiazepines in paper I is higher 
because reported use also include benzodiazepines acquired at the illegal market, something which 
is not captured in paper III.   
 
A high proportion of pregnant OMT women experience depression [48, 157, 158] and psychiatric 
problems are associated with negative pregnancy outcomes [159]. In paper II, 8 % of the women 
reported serious depression during the 30 days prior to the EuropASI interview and 36 % were 
classified as “cases” on depressive symptoms during the last week according to SCL-25, conducted 
during third trimester. However, in paper III only 5 % of the OMT women were prescribed 
antidepressants during pregnancy in Norway. In comparison, 24 % of pregnant opioid dependent 
women in an study including data from the U.S., Austria and Canada received SSRI during pregnancy 
[44], and in a Norwegian study of OMT patients in general, 23 % of the women received at least one 
prescription of antidepressants during one year [160]. Among all women in the general population, 
7.9 % were dispensed an antidepressant drug at least once during 12 months [126]. The increase in 
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depression among OMT women in paper II, from six months to two years after the baby was born, is 
cause for concern. The women represent a vulnerable, high-risk group, given their history of 
substance abuse and psychiatric problems.  
 
If treatment providers fail to address depression in pregnant OMT women and do not provide 
appropriate treatment, this poses a major risk to the health of both the woman and the neonate 
[16]. Among the risks are: lower fetal growth and dysfunctional bonding between mother and child 
[161]. Pregnant OMT women should be carefully evaluated for depression and offered appropriate 
medication if the potential benefits of treating depression with pharmacological alternatives 
outweigh the risk of not doing so [40, 162]. Compared to the OMT patients in general in Norway, 
where only one in five that receive antidepressants received Tricyclic antidepressants (TCAs) [160], it 
is worth noting that TCA is as common as SSRI among pregnant women in OMT [160]. This may 
indicate that they receive antidepressants to treat pain [163]. 
  
Concerns have been raised regarding how stigma and fear of drug-seeking behavior, may result in 
over caution in prescribers [16]. This was probably not the case in the  present study however, since  
the proportion  of women who received strong and weak opioid analgesics was the same.  In 
comparison, among pregnant women in the general population that are dispensed opioid analgesics, 
99 % receive weak opioids [164]. Opioid dependence may be associated with increased sensitivity to 
pain, and tolerance to opioids, including opioid analgesics. [165-167] On this background, pain 
management in pregnant OMT women is challenging. In Norway the national guideline for pregnant 
OMT women offers suggestions to what pain medications should be used during birth. However, the 
guideline does not address how to treat pain earlier in pregnancy [40].  
 
Use of antiinfectives were about twice as high among pregnant women OMT women as in the 
general population of pregnant women [108, 168]. Prior life circumstances with injection drug use, 
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poor nutrition, poor personal hygiene, prostitution, co-morbidity  and stress,  which is associated 
with high prevalence of infections, may contribute to higher use of antiinfectives in OMT women [9, 
169].  
5.2.4. Aim IV: Maternal and neonatal outcomes from exposure to  different OMT drugs 
Findings in Paper IV suggest that there are no significant adverse maternal outcomes from use of 
buprenorphine + naloxone compared to buprenorphine and methadone. Neonates exposed to 
buprenorphine + naloxone were significantly shorter at birth and had significantly lower Apgar scores 
at 5 minutes compared to the buprenorphine group.  Only 10 women and neonates were included in 
the buprenorphine + naloxone group, and the findings on maternal and neonatal outcomes should 
therefore be considered preliminary. Since there is a lack of literature that compares buprenorphine 
+ naloxone to other medicinal treatments for opioid dependence in pregnant women, we were 
unable to compare our results to results from other studies.  
 
Only maternal and neonatal outcomes that could be measured objectively were included. For 
example, whether the women gave birth through cesarean section, complications at delivery and 
number of prenatal obstetrical visits. However, it may be questioned how objective the 
measurements of some of the outcomes really were. Anxiety and uncertainty among pregnant 
women and health care personnel without special competence on opioid dependence in pregnant 
women may have contributed to decisions to use cesarean section more often than in the general 
population. Furthermore, competence on scoring of NAS may be limited at some hospitals, which 
may lead to different practice for length of hospital stay and treatment of NAS [99].  
 
There is an ongoing debate regarding which OMT medication is the better choice for pregnant opioid 
dependent women. In Norway buprenorphine is the number one recommendation for opioid 
dependent individuals in general and also for pregnant women [12, 40]. Buprenorphine appears to 
be superior to methadone for some neonatal outcomes: shorter duration of NAS and shorter hospital 
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stay to treat NAS [86, 88-90, 170-173]. However, sometimes a patient does not respond well to 
buprenorphine, or simply prefers methadone over buprenorphine [16, 74]. Therefore, both 
treatment options should be available.  The safety of buprenorphine + naloxone has not been 
sufficiently studied yet, and should generally not be used to treat pregnant opioid dependent women 
before the woman has tried buprenorphine alone. More research should be conducted before use of 
buprenorphine + naloxone is recommended to pregnant opioid dependent women.   
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6.0 FUTURE RESEARCH 
Ethical considerations has to be taken, when studying vulnerable groups such as pregnant women in 
OMT. Researchers and clinicians should to be careful not to make the women feel pressured into 
participating in research projects. However, not conducting research on this patient group would be 
equally problematic, since research is needed in order to offer the best possible knowledge-based 
treatment. Furthermore, we need to carefully consider how we can best contribute to this in a small 
country such as Norway, where conducting clinical research on pregnant women in OMT is 
challenging, because the number of pregnant OMT women is quite low. Clinical and epidemiological 
studies complement each other,  and contribute to a more complete picture of pregnant women in 
OMT. 
 
Limited knowledge exists on long term outcomes in the children exposed to OMT and co-medication 
and more research is needed on long term outcomes to investigate if children exposed to OMT and 
co-medication are more prone to diseases or early deaths, than children exposed to only OMT and 
children in the general population. 
 
With a high prevalence of psychiatric and somatic problems [4, 49], co-medication with other 
prescription drugs is common among pregnant OMT women. Knowledge of potential risks from co-
medication among pregnant OMT women is scarce, incomplete and lacks details of the potential 
effects on pregnancy and neonatal outcomes. Consequently, pregnant OMT women may not receive 
the medications they need for psychiatric symptoms and pain, because prescribing doctors lack 
knowledge on OMT and co-medication during pregnancy. Prescribing doctors may also be concerned 
about increased risk of adverse pregnancy and neonatal outcomes, as well as drug seeking behavior 
and overmedication [174]. Conversely, some women receive co-medication that may be harmful, 
such as benzodiazepines which may increase the risks of adverse outcomes, including prevalence of, 
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and prolonged treatment of NAS [175, 176]. Both over and under-medication endangers treatment 
stability and may cause a relapse to illegal substance use. Co-medication may contribute substantially 
to adverse pregnancy and neonatal outcomes [176]. At this point it can only be speculated whether 
this is due to the combination of prescription drugs themselves, or if the women that receive these 
prescription drugs have more health problems, and therefore higher probability of adverse 
pregnancy and neonatal outcomes. Therefore, large scale high quality studies are warranted to 
produce findings that may reduce the high societal and personal costs that accompany these 
outcomes [177]. 
 
OMT has become the main treatment intervention for heroin dependence, in Norway and many 
other countries; also for women of childbearing age. In recent years most patients in Norway are 
dispensed OMT drugs in pharmacies. Dispensed prescription drugs in Norway are recorded in the 
prescription registers which offers a new opportunity to study OMT patients. In Norway, several 
studies have already described co-medication among OMT patients in general [160, 178], and paper 
III in the present thesis looked specifically at co-medication among pregnant OMT women .  
 
However, to study the important consequences of such treatment, there is a need for more data 
than what is available in Norway. An overall Nordic cohort may offer the size necessary to study 
these outcomes. Each Nordic country has national registers, which include prospectively collected 
information on the health of all inhabitants. Linking and investigating data in the prescription 
databases, birth registries, cause of death registries, patient registries and data on socio-economic 
status from the statistical central bureaus in the Nordic countries may produce findings on new and 
reliable knowledge on pregnant women in OMT and their children.  
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7.0 CONCLUSIONS 
The thesis contribute to increased knowledge regarding  substance abuse and psychiatric problems 
among pregnant women in OMT in Norway and their partners. The thesis contribute to a reduction in 
the knowledge gap regarding prescription drugs  among pregnant OMT women, and awareness 
regarding maternal and neonatal outcomes from exposure to buprenorphine + naloxone compared 
to other medicinal treatment options  for opioid dependence among pregnant women. 
 
The main findings and implications of the present study can be summarized as: 
 Use of illegal substances was low both during third trimester and one year after the birth among 
the women and their partners. The increase in problem drinking among the women one year 
after birth may indicate that some women may not be coping with motherhood. 
 Psychiatric problems was low, relative to the OMT population, among the women and the 
partners alike both during the third trimester and one year after delivery.  
 A  high prevalence of PDs among both women and their partners, and the increase in depressive 
symptoms among women when the children were two years old, may compromise the child-
parent relationship.  It is therefore important that parents in OMT and their children are followed 
closely for several years after delivery.  
 Pregnant OMT women use more prescription drugs than  pregnant women in the general 
population. Particularly use of drugs acting on the central nervous system and antiinfectives 
were high.  
 Benzodiazepines were the most commonly used prescription drug, but use was reduced from 
prior to  pregnancy to third trimester.  
 Preliminary findings suggest no significant adverse maternal or neonatal outcomes related to the 
use of buprenorphine + naloxone for the treatment of opioid dependence. However, GPs should 
exercise caution when using buprenorphine + naloxone to treat opioid dependent pregnant 
women due to limited research. 
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ERRATA 
Paper I,  Table III, p values for “illegal substances sum” and “legal substance s sum” should be listed 
under the table instead of in own column.  For women the increase in use of legal substances from 8-
19 % from pregnancy to one year after was not significant (p =.08) whereas the reduction from 38-20 
% among the partners was significant (p = .01) 
Paper II, figure I. Last box for women should read “2years after birth”, not 1 year after birth 
Paper II. The reference “Hans, Bernstein, Henson” is listed twice in the reference list. 
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Abstract  
Objectives: Given that buprenorphine+naloxone is prescribed for opioid-dependent 
pregnant women, it is important to examine the extent to which it differs from buprenorphine 
alone, methadone, or methadone-assisted withdrawal on neonatal and maternal outcomes. 
Methods: All data presented are gathered from 7 previously published studies.  Not all 
studies from which data were extracted had data for all outcomes. 
Results: Differences in maternal and neonatal outcomes from exposure to 
buprenorphine+naloxone during pregnancy compared to buprenorphine alone, methadone, 
or methadone-assisted withdrawal were non-existent or small. 
Conclusions: These preliminary findings suggest no significant adverse maternal or 
neonatal outcomes related to the use of buprenorphine+naloxone for the treatment of opioid 
dependence during pregnancy.  However, further research should examine possible 
differences between buprenorphine+naloxone and buprenorphine alone or methadone in 
fetal physical development. Patient preference, individual risk:benefit ratio, and treatment 
context should be considered when prescribing any medication during pregnancy. 
 
Key words: buprenorphine; methadone; opioid dependence; pregnancy; neonates 
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Background 
Since the late 1960s methadone has been prescribed to pregnant women to treat 
opioid dependence (Blinick, 1968). Research conducted during the last decade indicates 
that maternal outcomes following use of buprenorphine during pregnancy are similar to 
maternal outcomes following use of methadone during pregnancy (Fischer et al., 2006; 
Jones et al., 2005; Jones et al., 2010; Kakko, Heilig, & Sarman, 2008; Lejeune, Simmat-
Durand, Gourarier, & Aubisson, 2006; Siedentopf, Nagel, Eßer, Casteleyn, & Dudenhausen, 
2004). However, buprenorphine seems to be superior to methadone in regard to some 
neonatal outcomes, including yielding a shorter duration of neonatal abstinence syndrome 
(NAS) and a shorter length of hospital stay (Binder & Vavrinkova, 2008; Colombini et al., 
2008; Fischer et al., 2000; Johnson, Jones, & Fischer, 2003; Jones et al., 2005; Kakko et al., 
2008; Schindler et al., 2003; Whitham et al., 2010).  
To date, research on the use of buprenorphine during pregnancy has focused almost 
exclusively on buprenorphine alone rather than the most commonly prescribed form of 
buprenorphine in the U.S., buprenorphine+naloxone. Buprenorphine+naloxone has been the 
preferred form of prescribed buprenorphine due to its reduced abuse liability relative to 
buprenorphine alone (Fudala et al., 2003; Strain, Harrison, & Bigelow, 2011).  This emphasis 
on buprenorphine alone is largely due to two reasons. First, pregnant women are advised to 
limit fetal exposure to exogenous compounds, thus prescribing buprenorphine alone avoids 
fetal exposure to naloxone.  Second, data from animal studies suggest that prenatal 
exposure to naloxone may produce maternal and subsequently fetal hormonal changes 
(Brunton et al., 2005; Douglas, Meddle, Toschi, Bosch, & Neumann, 2005).  
Little is known about buprenorphine+naloxone relative to either buprenorphine alone, 
methadone, or methadone-assisted withdrawal in the treatment of opioid dependence during 
pregnancy.  Buprenorphine+naloxone is now being prescribed to opioid-dependent pregnant 
women. It is therefore important to examine whether neonatal and maternal treatment 
outcomes for pregnant women in treatment for opioid dependence with 
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buprenorphine+naloxone differ from these outcomes for pregnant women in treatment for 
opioid dependence with buprenorphine, methadone, or methadone-assisted withdrawal. 
The three objectives of the present study are to compare neonatal and maternal 
outcomes from a group of opioid-dependent women who were prescribed 
buprenorphine+naloxone during their pregnancy to: (1) groups of opioid-dependent pregnant 
women who were prescribed buprenorphine alone; (2) groups of opioid-dependent pregnant 
women prescribed methadone; and (3) a group of opioid-dependent pregnant women who 
underwent a 7-day methadone-assisted withdrawal.   
Methods 
All data presented in this review come from previously published studies (Czerkes, 
Blacstone, & Pulvino, 2010; Debelak, Morrone, O'Grady, & Jones, 2012, in press; Fischer et 
al., 2006; Jones et al., 2005; Jones et al., 2010; Jones, O'Grady, Malfi, & Tuten, 2008; Metz 
et al., 2011), which represented a wide range of studies on use of buprenorphine and 
methadone during pregnancy. However, several authors of these papers provided additional 
data (e.g., standard deviations) that were not available in their published papers. The articles 
included were chosen because they represented a range of study methodologies; RCTs and 
retrospective studies, increasing generalizability of the findings.  Moreover, all studies 
reported a common subset of outcome measures, and provided data that could be easily 
subject to re-analysis. 
Studies 
Buprenorphine+naloxone: an initial study of maternal and neonatal safety 
Debelak et al.  (2012) conducted a retrospective chart review in a community health 
setting that produced 10 women who had received buprenorphine+naloxone during the 
course of their pregnancies. Maternal outcomes reported in this study were: cesarean 
section, days of maternal hospital stay, maternal weight gain, non-normal presentation, 
analgesia during delivery, drug-screen at delivery, medical complications at delivery, number 
of prenatal obstetrical visits, fetal presentation at delivery and breastfeeding following 
delivery. Neonatal outcomes included were: treated for NAS, total amount of morphine for 
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NAS, days treated for NAS, days of infant hospital stay, head circumference, birth weight, 
infant length, pre-term birth, gestational age at delivery, Apgar scores at 1 and 5 minutes. 
They reported neonatal growth parameters within normal limits, with only 40% of the 
neonates treated for NAS. Mean number of days with NAS treatment was 6.9 (SD=10.1). 
Findings indicated that there were no obvious adverse maternal or neonatal outcomes 
related to the use of combination buprenorphine+naloxone product for treatment of opioid-
dependence in pregnant women.  Maternal outcomes were similar to what has been found 
for women using buprenorphine alone. 
Comparing maternal and/or neonatal outcomes; methadone v. buprenorphine 
Czerkes et al. (2010) conducted a retrospective chart review from 2004-2008 that 
examined differences in outcomes in neonates born to women who had been prescribed 
methadone (n=101) or buprenorphine (n=68) during pregnancy. Exclusion criteria’s were: 
delivery not performed at Maine Medical Center and preterm delivery (before 37 weeks of 
gestation).The following neonatal outcomes were measured: treated for NAS, length of stay, 
neonatal abstinence score, neonates requiring treatment, birth weight, Cord pH, 1 and 5 
minute Apgar scores. The Finnegan scale was used to evaluate NAS scores. Neonates in 
the buprenorphine group had a lower mean NAS score than neonates in the methadone 
group.  Number of neonates (48.8 % v. 73.3%, p<.001) treated for NAS and mean length of 
hospital stay (8.4 v. 15.7 days, p<.0001) of those neonates treated were also significantly 
lower in the buprenorphine group.  Analyses also revealed no significant differences in 
maternal characteristics between the two groups.   
Fischer et al. (2006) conducted a randomized, double-dummy, double-blind, flexible-
dosing trial comparing buprenorphine to methadone in opioid-addicted pregnant women to 
evaluate safety and efficacy of the two medications in pregnant women.  Inclusion criteria’s 
were: informed consent, willing to follow protocol and not use illegal drugs. Women with high 
risk pregnancies, additional severe psychiatric or somatic diseases were excluded. The 
maternal outcome reported, separately for buprenorphine and methadone conditions, was 
cesarean section. Neonatal outcomes reported were: treated for NAS, total amount of 
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morphine for NAS, days treated for NAS, birth weight, pre-term birth, gestational age at 
delivery, Apgar scores at 1 and 5 minutes. The Finnegan scale was used to assess NAS. 
Eighteen women were randomly assigned to either buprenorphine or methadone.  There 
were 6 women in the methadone and 8 women in the buprenorphine condition at delivery.  
Methadone dose ranges were 40-100 mg while buprenorphine dose ranges were 8-24 mg. 
Retention was higher in the buprenorphine condition, whereas methadone was more 
effective than buprenorphine in preventing use of additional opioids (p<.05).  
Metz et al. (2011) examined maternal and neonatal outcome in pregnant opioid-
maintained women in a randomized clinical trial compared to a group of women undergoing 
a structured standard pharmacotherapy protocol with either buprenorphine or methadone at 
the Medical University of Vienna. The women included in the randomized controlled trial 
portion were part of Jones et al. (2010). Therefore, only data from the women that underwent 
structured standard pharmacotherapy protocol with either buprenorphine or methadone were 
included in the present paper. Inclusion criteria were: 18 to 41 years of age, single fetus 
pregnancy, and that they were not drop-outs from the clinical trial in the same study. Women 
were excluded from the study if they had an abortion, miscarriage or decided to deliver at 
another clinic. The maternal outcomes reported were cesarean section and urine toxicology 
during the third trimester. The neonatal outcomes reported were: treated for NAS, total 
amount of morphine for NAS, days treated for NAS, days of hospital stay, head 
circumference, birth weight, infant length, gestational age at delivery, Apgar scores at 1 and 
5 minutes. NAS was assessed using a modified version of the Finnegan scale. Opioid 
maintenance medication was determined on an individualized basis and chosen according to 
patient preference for buprenorphine or methadone as well as medical criteria. Maternal 
outcomes were fairly similar in the buprenorphine and methadone groups, apart from more 
positive urine toxicologies overall in the methadone than the buprenorphine group. Neonatal 
outcomes were superior in the buprenorphine than in the methadone group in terms of 
gestational age at delivery and the following physical characteristics:  body length, body 
weight, and head circumference.  Fewer neonates in the buprenorphine group needed NAS 
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treatment and among neonates who did need treatment, total morphine dose was lower and 
days of morphine treatment were fewer compared to neonates in the methadone group.  
   Jones et al. (2005) conducted a randomized, double-blind, double-dummy, flexible-
dosing parallel-group controlled trial that compared NAS in neonates born to women 
maintained on buprenorphine or methadone. Inclusion criteria’s were: age 21-40 years, 
estimated gestational age 16-30 weeks,  currently meet DSM  IV criteria for opioid 
dependence,  asking for maintenance therapy, report using opioids > 4 days during the past 
7 days, and positive urine sample at intake. Exclusion criteria’s were: positive urine sample 
for undocumented methadone at intake, Alcohol abuse or dependence according to DSM IV 
criteria, using benzodiazepines > 7 days per month or more than >1 per week . Women that 
receive co-medication for other axis I disorder or have a serious medical illness than may 
compromise study participation were also excluded. Thirty women who met all of the 
eligibility criteria were randomized to either the buprenorphine or methadone condition. At 
delivery, 11 women in the methadone and 9 in the buprenorphine group had completed the 
study. Maternal outcomes reported were: cesarean section, days of hospital stay, non-
normal presentation, analgesia during delivery, drug screen at delivery and maternal medical 
complications. Neonatal outcomes included were: treated for NAS, total amount of morphine 
for NAS, NAS peak score, days of infant hospital stay, head circumference, birth weight, 
infant length, pre-term birth, gestational age at delivery, Apgar scores at 1 and 5 minutes. A 
modified 19-item Finnegan Scale was used to assess NAS.  Morphine sulfate was the 
pharmacotherapy treatment for NAS. Two of ten (one woman gave birth to twins) neonates 
(20%) exposed to buprenorphine and 5 of 11 (45.5%) exposed to methadone were treated 
for NAS. The total amount of morphine solution to treat NAS was three times higher in the 
methadone condition than in the buprenorphine condition, although this difference was not 
significant (93.1 v. 23.6; p=.3). Length of hospitalization was significantly shorter for 
buprenorphine- than for methadone-exposed neonates (p=.02).  
Jones et al. (2010) conducted a double-blind, double-dummy, flexible-dosing, 
randomized study comparing use of buprenorphine and methadone in 175 pregnant women 
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in comprehensive care at seven international sites. Of the 131 neonates born to the mothers 
followed to the end of their pregnancies, 73 were exposed in utero to methadone and 58 to 
buprenorphine.  Exclusion criteria’s were: medical or other condition that may compromise 
participation in the study, pending legal action that may contradict participation and disorders 
related to use of alcohol or benzodiazepines. The following maternal outcomes were 
reported: cesarean section, days of maternal hospital stay, maternal weight gain, non-normal 
presentation, analgesia during delivery, drug-screen at delivery, medical complications at 
delivery, number of prenatal obstetrical visits. Neonatal outcomes reported were: treated for 
NAS, total amount of morphine for NAS, days treated for NAS, days of infant hospital stay, 
head circumference, birth weight, infant length, pre-term birth, gestational age at delivery, 
Apgar scores at 1 and 5 minutes. NAS was assessed using a modified Finnegan Scale. 
Dose adjustments were based on medication adherence, urine toxicology results, participant 
request, and self-reported symptoms of craving or withdrawal. Hospitalized neonates were 
examined every 4 hours by trained staff, while NAS scores were obtained twice a day for 
neonates already released to their homes. The mean morphine sulfate dose required to treat 
the buprenorphine-exposed neonates were significantly lower (1.1 mg v. 10.4 mg, p<.01) 
than the dose for methadone-exposed neonates. Buprenorphine-exposed neonates also 
required a significantly shorter hospital stay (10 days v. 17.5 days, p<.01) and duration of 
treatment for NAS (4.1 days v. 9.9 days, p<.01).  
Maternal and neonatal outcomes: methadone maintenance v. methadone taper 
  Jones et al. (2008) conducted a retrospective record review that compared neonatal 
and maternal outcomes in pregnant women in treatment for opioid dependence.  The women 
received either continuous methadone maintenance (n=52) or seven-day (n=28) methadone 
assisted withdrawal.  The women were not randomized to these treatment options. 
Methadone-assisted withdrawal inclusion criteria included: meeting and refusing methadone 
maintenance criteria, receiving a prescription for 3 or 7 days of methadone assisted 
withdrawal, were not receiving medication assisted taper for benzodiazepines or alcohol. 
Medical charts and complete information on delivery outcome had to be available at Johns 
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Hopkins Bayview Medical Center. The maternal outcomes reported were: positive drug 
screen at delivery. Neonatal outcomes were: treated for NAS, days of infant hospital stay, 
head circumference, birth weight, infant length, pre-term birth, gestational age at delivery, 
and Apgar score at 1 and 5 minutes. The proportion of women with positive urine toxicology 
tests for illegal drugs at delivery was more than twice as high (57%) among women in 7-day 
detoxification compared to women in methadone maintenance (23%). Women in methadone 
maintenance attended more obstetrical visits and remained in treatment longer than the 
women with 7-day methadone-assisted withdrawal. 
Outcome Measures 
Neonatal outcomes. Summary descriptive statistics (frequencies or means and 
standard deviations) for 10 neonatal outcomes were extracted from the above articles: 
Treated for NAS (yes v. no), Total amount of morphine used to treat NAS (mg), number of 
days treated for NAS, infant length of hospital stay, Pre-term (<37 weeks) birth, estimated 
gestational age at delivery (weeks), Apgar scores at 1 and 5 minutes, infant head 
circumference (cm), birth weight (gm), and length (cm).  
Maternal outcomes.  Summary descriptive statistics (frequencies or means and 
standard deviations) for 8 maternal outcomes were extracted from the above articles: 
whether the women gave birth through cesarean section (yes v. no), days of maternal 
hospital stay, maternal weight gain (kg), non-normal presentation of fetus at delivery (yes v. 
no),  used analgesia during delivery (yes v. no) , positive drug screening (for opioids [other 
than their study medication], cocaine, barbiturates, benzodiazepines) at delivery (yes v. no), 
medical complications at delivery (yes v. no), and number of prenatal obstetrical visits.  
Statistical Analysis 
 Two different types of summary statistics were collected from articles that provided 
comparison data: frequencies for binary variables (e.g., Treated for NAS: yes v. no) and 
means and standard deviations for continuous variables (e.g., Total amount of morphine for 
NAS).  Data were not available for all outcome variables in every article.  However, because 
frequencies were available for the binary outcomes and means and standard deviations 
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were available for the continuous outcomes for the respective groups in each comparison 
article for which data were available, it was possible to utilize logistic regression to analyze 
the binary data using an events/trials approach.  Because some of the cells for studies that 
did yield data had zero or very small frequencies, Firth’s penalized maximum likelihood 
approach was utilized to conduct tests of significance for the logistic regression analyses 
(Firth, 1993). Oneway analysis of variance was employed to analyze the continuous 
outcome data, making use of the summary statistics (Larson, 1992). 
 In order to address the three questions posed in this study, three single-degree-of-
freedom, non-orthogonal planned contrasts were created for each outcome measure.  The 
first planned contrast compared the buprenorphine+naloxone group to the available 
buprenorphine groups, pooled, which addressed the question of whether or not 
buprenorphine+naloxone produces superior neonatal and/or maternal outcomes relative to 
buprenorphine.  The second planned contrast compared the buprenorphine+naloxone group 
to the available methadone groups, pooled, which addressed the question of whether or not 
buprenorphine+naloxone produces superior neonatal and/or maternal outcomes relative to 
methadone.  The third planned contrast compares buprenorphine+naloxone to 7-day 
methadone-assisted withdrawal, which addressed the question of whether or not 
buprenorphine+naloxone produces superior neonatal and/or maternal birth outcomes 
relative to methadone-assisted withdrawal.  The error term for all contrasts in the oneway 
ANOVAs was the within cells term (as in ‘standard’ oneway ANOVA).   
 Due to the relative complexity of the proposed contrasts, the last row of Table 1 
illustrates the set of coefficients that would be used for the outcome variable total amount of 
morphine for NAS in order to compare the mean of the buprenorphine+naloxone group to 
the pooled means of the Fisher et al. (2006), Jones et al. (2005), and Jones et al. (2010) 
comparison samples.  In this case, x indicates data were missing for the respective 
comparison group, zero indicates data were available for that comparison sample, but 
weren’t included in the contrast – in this case because the data in question were for 
methadone – while the non-zero values indicates that the buprenorphine+naloxone mean is 
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being compared to the unweighted average of the means of the three comparison samples 
with buprenorphine data.  Thus, this comparison is the ‘standard’ oneway ANOVA contrast 
among means, which would likewise use the unweighted average of the means for a 
planned contrast.   
Results 
 In general, the samples were similar in maternal age (mean age range was 23.9-30.3 
years).  [Demographic data other than age were not consistently available in the studies in 
order to present a general summary.] Only two studies reported opioid-agonist medication 
dose at delivery:  Metz et al. (2001) reported mean methadone dose of 74.2 and 
buprenorphine dose of 9.9, while Jones et al. (2010) reported means of 79.1 and 18.7, 
respectively. 
Table 1 contains the frequencies (percentages) or means (standard deviations) of the 
outcome measures available in each study. Table 2 contains results for maternal and 
neonatal outcomes. 
Maternal outcomes 
There were no significant differences in maternal outcomes for women exposed to 
buprenorphine+naloxone compared to women exposed to buprenorphine, methadone, or 
methadone-assisted withdrawal.  
Neonatal outcomes 
Head circumference was significantly higher on average among neonates exposed in 
utero to buprenorphine+naloxone compared to neonates exposed to methadone-assisted 
withdrawal [Ms=32.8 (SE=.60) v. 31.2 (SE=.36), F(1, 307)=5.24, p<.03, while neonates 
exposed in utero to buprenorphine+naloxone were shorter on average than neonates 
exposed to buprenorphine  [Ms = 46.3 (SE=1.08) v. 50.56 (SE=.51), F(1, 307) =12.74, 
p<.001], although both groups were within the normal range according to  the WHO 
international standards of child growth (WHO, 2006).  Mean Apgar scores at 5 minutes were 
significantly lower in the buprenorphine+naloxone group compared to the buprenorphine 
alone group [Ms= 8.6 (SE=.29) v. 9.6 (SE=.12), F(1, 499)=4.88, p<.03]. 
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Discussion 
The present evaluation of buprenorphine+naloxone suggests that maternal and most 
neonatal outcomes from exposure to buprenorphine+naloxone are not dissimilar from those 
same outcomes found in women and their neonates exposed to buprenorphine and 
methadone. 
Findings suggest that rates of cesarean section, non-normal presentation, analgesia 
during delivery, screening positive for illicit substances, and medical complications at 
delivery, together with length of maternal hospital stay, maternal weight gain, and number of 
prenatal visits for women using buprenorphine+naloxone during pregnancy do not differ 
significantly from women using either buprenorphine or methadone.  These findings are not 
surprising, given previous research has indicated that maternal outcomes are comparable 
across buprenorphine and methadone treatment (Fischer et al., 2006; Jones et al., 2005; 
Jones et al., 2010; Kakko et al., 2008; Lejeune et al., 2006; Siedentopf et al., 2004).  
There were three significant differences in neonatal outcomes when neonates 
exposed to buprenorphine+naloxone were compared to neonates exposed to buprenorphine 
alone, methadone, or 7-day methadone-assisted withdrawal.  Head circumference in the 
buprenorphine+naloxone group was significantly greater than in the 7-day methadone-
assisted withdrawal group.  Neonates in the buprenorphine+naloxone group were 
significantly shorter at birth compared to the buprenorphine alone group. However, the birth 
parameters of the buprenorphine+naloxone group were within normal birth parameters 
(Debelak et al., 2012, in press).  Apgar scores at 5 minutes were significantly lower in 
neonates in the buprenorphine+naloxone group compared to neonates exposed to 
buprenorphine alone; however, the mean Apgar scores for both groups are considered 
normal and not clinically concerning. There were no significant differences between the 
groups on any other neonatal outcome measures: treated for NAS, total amount of morphine 
used in treatment of NAS, days treated for NAS, days of infant hospital stay, preterm birth, 
gestational age at delivery, and Apgar scores at 1 minute.  Although not significant, the 
differences in birth length between the neonates in the buprenorphine+naloxone group and 
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the neonates in the buprenorphine alone group may be related to differences (although not 
significant) between the groups in gestational age. Although these birth parameters are 
within the normal range, future studies should consider investigating these potential 
differences further. 
 Limitations:  The strength of any inferences from the present findings must be 
tempered by the fact that the sample size for buprenorphine+naloxone was small.  
Moreover, use of summary descriptive statistics to conduct inferential analyses does not 
allow examination of the extent to which violation of the statistical assumptions might have 
impacted the findings.  Data were only collected for neonates and mothers where pregnancy 
ended in live births. Therefore, we lack information about abortion frequency and 
miscarriage, which is potentially important information when comparing medications for 
opioid dependence in pregnant women.  Finally, the various studies under review used 
various forms of the Finnegan scale to assess neonatal abstinence syndrome. 
It is also true that some factors were uncontrolled in several studies included in the 
present article. For example, there is no available information on use of illicit substances, 
depression, exposure to sexual victimization, physical violence, or inadequate nutrition in 
Czerkes et al. (2010) and Debelak et al. (2012). Thus, analyses in the present study cannot 
control for such factors that may account for some degree of the differences between 
medications in neonatal outcomes (Kaltenbach, Berghella, & Finnegan, 1998). Assessment 
of the benefits and risks for opioid-dependent pregnant women associated with 
buprenorphine+naloxone, buprenorphine alone, methadone, and methadone-assisted 
withdrawal can best be undertaken when such factors are taken into consideration (Jones et 
al., 2012).   
Pooling data from randomized controlled trials with data from retrospective chart 
reviews offers challenges. For example, information regarding factors such as exclusion of 
preterm births is not included in all the studies. There is a lack of background information on 
the women, such as information on what kind(s) of treatment in addition to their medication, 
when they started their medication and medication dose. Hence, it is uncertain how 
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comparable the women in these studies are to the women in the randomized controlled trials 
where information regarding inclusion and exclusion criteria was available. these same 
challenges are present in the conduct of meta analyses, which must attempt to aggregate 
data across research studies.  Most meta-analyses have focused on the characteristics of 
the studies under evaluation – such as whether or not a study is a randomized controlled 
trial – with little attention to these same issues of patient, treatment, and outcome measure 
similarities.  Rather than focus on such a narrow bandwidth in the choice of our studies, we 
determined to choose representatively among studies that would provide us with similarity of 
outcome information.  As with most meta-analyses, such an effort at breadth was done at 
the cost of choosing studies whose patient populations and treatment characteristics were 
substantially different.  However, the gain in our strategy of choosing a representative 
sample of studies across the spectrum of designs was on the potential generalizability of the 
findings, and allows for an examination of the extent to which there is enough signal in the 
medication differences to overcome the heterogeneity of study characteristics. 
 There are still unanswered questions about the maternal and neonatal safety of 
buprenorphine+naloxone. The neonatal outcomes (Debelak et al., 2012, in press) presented 
in the present study would benefit from confirmation from other and larger samples of 
women.  
It is important to note that in most U.S. locales, buprenorphine+naloxone may be the 
only buprenorphine treatment available to pregnant women.  In other nations, such as 
Norway for example, buprenorphine alone is the recommended opioid medication for 
pregnant women with opioid dependence (Bakstad, 2011).  Pregnant women already in 
buprenorphine+naloxone treatment are encouraged to transfer to buprenorphine alone. This 
recommendation is based on the existing research on maternal and neonatal safety of 
buprenorphine alone and the lack of research investigating the safety of 
buprenorphine+naloxone during pregnancy.  
Strengths: This is the first comparison of neonatal and maternal outcomes from 
exposure to buprenorphine+naloxone to the other available treatment options for opioid-
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dependent pregnant women: buprenorphine, methadone, and methadone-assisted 
withdrawal. 
Conclusions 
Findings from the present study suggest no obvious significant adverse maternal 
outcomes related to the use of buprenorphine+naloxone for the treatment of opioid 
dependence in pregnancy. The birth parameters for the neonates in the 
buprenorphine+naloxone group were within the normal range. However, the potential for 
lower neonatal birth length, weight, and head circumference in this group merit further 
research on neonatal physical development, and suggests caution in the use of 
buprenorphine+naloxone. Larger samples are necessary to further examine the relative 
neonatal safety of buprenorphine+naloxone for the treatment of opioid-dependent pregnant 
women. 
Clinical Implications:  The advent of buprenorphine+naloxone has brought a new 
treatment option for opioid-dependent pregnant women and new challenges to clinicians 
regarding rational decision-making about which treatment option is the most appropriate for 
their opioid-dependent pregnant patients.  Clinicians who choose to treat their opioid-
dependent pregnant patients with buprenorphine+naloxone may need to closely monitor the 
neonates of their patients in terms of their fetal and neonatal outcomes, until further research 
has addressed this issue. The data on the safety of buprenorphine+naloxone is not sufficient 
for the medication to be recommended to pregnant women. Buprenorphine alone should be 
available for opioid-dependent pregnant women, because the maternal and neonatal safety 
of this medication has been investigated and the collective results suggest that, when taken 
as a part of a treatment program, it has an acceptable safety profile for both mother and 
child (Fischer et al., 2006; Jones et al., 2005; Jones et al., 2010; Metz et al., 2011). Patients' 
preference, side effects, and retention in treatment should be evaluated carefully.  
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Table 2.  Results for Tests of Significance for Planned Contrasts
Outcome measure Planned Contrast Test Statistic p
NEONATAL:
Treated for NAS Buprenorphine+naloxone  v.  Buprenorphine 2(1)=.03 .86
Buprenorphine+naloxone  v. Methadone 2(1)=1.36 .24
Buprenorphine+naloxone  v. 7-day 
methadone-assisted withdrawal 
2(1)=.06 .81
Total amount of Morphine for NAS:
      All neonates* Buprenorphine+naloxone  v.  Buprenorphine F(1, 168)=.00 .99
Buprenorphine+naloxone  v. Methadone F(1, 168)=.20 .66
Total amount of Morphine for NAS: 
      Neonates treated for NAS* Buprenorphine+naloxone  v.  Buprenorphine F(1, 80)=.00 .95
Buprenorphine+naloxone v. Methadone F(1, 80)=.13 .72
Days treated for NAS:
     All neonates‡ Buprenorphine+naloxone  v.  Buprenorphine F(1, 150)=.09 .77
Buprenorphine+naloxone  v. Methadone F(1, 150)=.22 .64
Days treated for NAS:
     Neonates treated for NAS‡ Buprenorphine+naloxone  v.  Buprenorphine F(1, 119)=.52 .47
Buprenorphine+naloxone  v. Methadone F(1, 119)=.14 .71
Days of infant hospital stay Buprenorphine+naloxone  v.  Buprenorphine F(1, 476)=.02 .90
Buprenorphine+naloxone  v. Methadone F(1, 476)=3.46 .06
Buprenorphine+naloxone  v. 7-day 
methadone-assisted withdrawal F(1, 476)=.07 .80
Head circumference Buprenorphine+naloxone v.  Buprenorphine F(1, 307)=3.10 .08
Buprenorphine+naloxone  v. Methadone F(1, 307)=.13 .72
Buprenorphine+naloxone  v. 7-day 
methadone-assisted withdrawal F(1, 307)=5.24 .02
Birthweight Buprenorphine+naloxone  v.  Buprenorphine F(1, 486)=2.99 .08
Buprenorphine+naloxone  v. Methadone F(1, 486)=.03 .87
Buprenorphine+naloxone  v. 7-day 
methadone-assisted withdrawal F(1, 486)=.00 .97
Length Buprenorphine+naloxone  v.  Buprenorphine F(1, 307)=12.74 <.001
Buprenorphine+naloxone  v. Methadone F(1, 307)=3.84 .051
Buprenorphine+naloxone  v. 7-day 
methadone-assisted withdrawal F(1, 307)=.90 .33
Pre-term birth Buprenorphine+naloxone  v.  Buprenorphine 2(1)=.89 .34
Buprenorphine+naloxone  v. Methadone 2(1)=.01 .91
 
Outcome measure Planned Contrast Test Statistic p
Buprenorphine+naloxone  v. 7-day 
methadone-assisted withdrawal 
2(1)=.60 .44
Gestational age at delivery Buprenorphine+naloxone  v.  Buprenorphine F(1, 486)=2.72 .10
Buprenorphine+naloxone  v. Methadone F(1, 486)=.83 .36
Buprenorphine+naloxone  v. 7-day 
methadone-assisted withdrawal F(1, 486)=.04 .84
Apgar 1 minute Buprenorphine+naloxone  v.  Buprenorphine F(1, 488)=.72 .40
Buprenorphine+naloxone  v. Methadone F(1, 488)=.52 .47
Buprenorphine+naloxone  v. 7-day 
methadone-assisted withdrawal
   F(1, 488)=.04 .84
Apgar 5 minutes Buprenorphine+naloxone  v.  Buprenorphine F(1, 499)=4.88 .03
Buprenorphine+naloxone  v. Methadone F(1, 499)=3.61 .06
Buprenorphine+naloxone v. 7-day 
methadone-assisted withdrawal F(1, 499)=.09 .77
MATERNAL:
Cesarean section Buprenorphine+naloxone v.  Buprenorphine 2(1)=.24 .62
Buprenorphine+naloxone  v. Methadone 2(1)=.16 .69
Days of maternal hospital stay Buprenorphine+naloxone v.  Buprenorphine F(1, 156)=.02 .89
Buprenorphine+naloxone  v. Methadone F(1, 156)=.02 .89
Maternal weight gain Buprenorphine+naloxone  v.  Buprenorphine F(1, 138)=.18 .68
Buprenorphine+naloxone  v. Methadone F(1, 138)=.14 .70
Non-normal presentation Buprenorphine+naloxone v.  Buprenorphine 2(1)=2.16 .14
Buprenorphine+naloxone  v. Methadone 2(1)=1.33 .25
Analgesia during delivery Buprenorphine+naloxone  v.  Buprenorphine 2(1)=1.87 .17
Buprenorphine+naloxone  v. Methadone 2(1)=.76 .38
Drug screen at delivery Buprenorphine+naloxone  v.  Buprenorphine 2(1)=.02 .90
Buprenorphine+naloxone  v. Methadone 2(1)=.39 .53
Buprenorphine+naloxone v. 7-day 
methadone-assisted withdrawal 
2(1)=3.8 .051
Medical complications at delivery Buprenorphine+naloxone  v.  Buprenorphine 2(1)=.09 .77
Buprenorphine+naloxone  v. Methadone 2(1)=.22 .64
Number of prenatal obstetrical visits Buprenorphine+naloxone  v.  Buprenorphine F(1, 138)=.03 .87
Buprenorphine+naloxone  v. Methadone F(1, 138)=.06 .81
Notes.  *, ‡ See Table 1 for an explanation for why there are two outcome measures for total amount of morphine for 
NAS and days treated for NAS.
 
